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1.INTRODUCTION 
           Immune status, individual response to disease and types of 
antibodies produced are  known to vary from person to person, place to 
place and  from population to population. A broad spectrum of specific 
auto antibodies  which are associated with specific rheumatic diseases, as 
noted in Western literature, has been  taken as a reference standard all 
over the world1. There is neither research work nor any data correlating 
the auto antibodies and their antinuclear antibody (ANA) patterns with 
the immune profile in the Indian population to date. 
          About12-15% of clinically recognizable pregnancies result in 
abortion.  “Abortion is defined as the loss of a fetus or embryo weighing  
≤ 500g, which would normally be at 20-22 complete weeks of gestation 
as per World Health Organisation”. (WHO 1977). 
No valid estimate of  incidence of abortion  is known, because 
denominator variable (=individuals at risk) not clear2. Around 1% of 
fertile couples have recurrent pregnancy loss of which, in 50% of patients 
the underlying cause remains unknown. Of the known causes, 
autoimmune factors contribute to 5-10% of recurrent pregnancy loss. 
 Autoimmune factors have been recognised as key factors in 
recurrent pregnancy loss, even in women with no clinically diagnosed 
autoimmune disease. 
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 The term  Bad Obstetric History(BOH)3,” is applied to pregnant 
women  where her present obstetric outcome is likely to be affected  
adversely by the nature of previous obstetric disaster”. In obstetrics, any 
complicating factor, known or unknown is likely to recur and if it recurs 
in two consecutive pregnancies, the chance of its recurrence in third 
pregnancy is highly probable 
1.2 Etiology of recurrent pregnancy loss3 
 The causes of recurrent fetal wastage are complex and most often 
obscure. More than one factor may operate in a case. Factors may be 
recurrent or non-recurrent. 
1.2.1First trimester abortion 
1.Genetic causes 
 It accounts for 3-5% of fetal wastage. Parental chromosomal 
abnormalities is a prove cause of  recurrent abortion. The most common 
abnormality is a balanced translocation. Risk of miscarriage in couples 
with a balanced translocation is more than 25%.However the chance of  
successful pregnancy even without treatment is 40-50%. 
2. Endocrine and metabolic 
 Poorly controlled diabetic patients may have an increased 
incidence of early pregnancy failure 
 Presence of thyroid autoantibodies is often associated with 
increased risk 
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 Luteal phase defect with less production of progesterone, interfers 
with endometrial maturation 
 Hyper-secretion of Luteinising hormone as seen in PCOS cases is 
associated with sub-fertility and higher miscarriages. 
3. Infection 
 Infections of genital tract may be responsible for sporadic 
spontaneous abortions.Trans-placental fetal infection  can occur with 
most microorganisms. 
4.Inherited Thrombophilia 
 This causes both early and late miscarriages due to intravascular 
thrombosis.Protein C resistance and factor V Leiden mutation is the most 
common cause. Hyperhomocystinemia is also a factor for recurrent 
miscarriages. 
5.Unexplained 
 In the majority, the cause remains unknown. 
 1.2.2 Second trimester abortion 
1.Anatomic abnormalities 
 These are responsible for  10-15% of recurrent pregnancy loss.The 
causes may be congenital or acquired. 
 Congenital anomalies may be due to defect in the mullerian duct 
fusion or resorption (eg; unicornuate, bicornuate, septate or double 
uterus) 
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 Acquired anomalies are intrauterine adhesions, uterine fibroids, 
endometriosis and cervical incompetence 
2.Chronic Maternal illness 
 This includes uncontrolled diabetes, atherosclerosis, 
haemoglobinopathies, chronic renal disease, inflammatory bowel disease. 
3.Infection         
 Syphilis, toxoplasmosis, Listeriosis may be responsible in some 
cases. 
1.3  Immune factors 
 Immunological association of mother and the fetus is double-
directional which is decided by presentation of antigen by the fetus and 
its recognition and reaction by the maternal immune system.Balanced 
immune response is mandatory to sustain pregnancy and any imbalance, 
can lead to  early wastage of conception. 
 Autoantibodies and auto-reactive helper T cells(Th-2 cells) induces 
self-reactivity which may lead to tissue damage that results in non-organ 
specific  disease like Systemic Lupus Erythematosus or organ specific 
diseases like  Hashimoto’s thyroiditis, Addison’s disease, type I diabetes 
mellitus. 
 The immunological  causes for abortions,  can be divided to 
autoimmune factors and alloimmune  factors. 
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 1.3.1Autoimmune factors 
          Presence of autoantibodies causes rejection of early pregnancy in 
30% of  women5.Antibodies responsible are: Antinuclear antibodies and 
Antiphospholipid antibodies: lupus anticoagulant, anticardiolipin 
antibodies. These women demonstrate a tendency to miscarriage at 
progressively lower gestational ages. Placental vascular atherosis, 
intervillus thrombosis, and decidual vasculopathy with fibrinoid necrosis 
are the immediate pathology for fetal loss.Pregnancy complications 
include miscarriages, intra-uterine growth retardation, pre-eclamptic 
toxaemia, still birth, pre-term labour and placental abruption. 
1.3.2 Alloimmune factors 
 There is failure of maternal recognition of trophoblast lymphocyte 
cross-reactive antigen(TLX).Consequently there is lack of production of 
blocking antibodies by the mother.This is due to sharing of Human 
Leucocyte Antigen between partners3. 
1.3.3 Autoimmunity- role in RPL 
 Any disturbance in humoral or cellular response or function causes 
immune reaction against self components, which are manifested as signs 
and symptoms in autoimmune disorders.Genetic or environmental or 
other unknown factors triggers, a break in self tolerance6. 
 Pregnancy is confronted with number of self and foreign antigens 
that modulate the immune system of the mother. If immune response of 
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mother is altered, frequent abortions  result. Autoimmune disorders   are 6 
to 10 times more common among women than men7, and are most likely 
to have their onset during the reproductive years.    
1.4.1 ANA prevalence global scenario 
 An estimated 9.8 million women are afflicted with one of the seven 
more common autoimmune diseases: lupus, scleroderma, rheumatoid 
arthritis, multiple sclerosis, inflammatory bowel disease, Sjogren's, and 
type 1 diabetes8. The prevalence estimate of SLE in the general 
population is approximately 40:100,000, but this condition may affect 
1:1000 women during pregnancy. It is estimated that 10% of all women 
with lupus are diagnosed with the disease either during pregnancy or in 
the immediate postpartum period9. 
1.4.2 ANA prevalence in Indian Scenario 
 In India, the prevalence of SLE is  3.2 per 1,00,000(Medscape),the 
overall  annual incidence being 5-100 per 100,000 populations;  more 
than 90% of the patients are females of  reproductive age10.  
 It is reported that nearly half of lupus pregnancies are normal, one-
fourth deliver premature babies, and one-fourh of patients suffer from 
recurrent miscarriages. 
 Autoimmune disorders  are  most likely to have their onset during 
the reproductive years. It is therefore common to encounter patients with 
these conditions during pregnancy. The predictive value of screening 
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patients for subclinical autoimmune disease has been a matter of 
controversy for decades.The risk of abortions is increased in some 
patients with autoantibodies, even before a clinical diagnosis could be 
made.                       
1.5.1  Pathophysiology of autoimmunity in women 
 Females are having higher CD4/CD8 ratio and higher levels of 
serum immunoglobulin M.Large amont of cytokines are produced by T-
helper cells. Sex steroids can induce autoimmune  process, because of 
their ability to modify immune response via their action through steroidal 
receptors. These  sex steroidal levels can fluctuate dramatically during 
gestation.This hormonal difference alone is insufficient for explaining sex 
difference in autoimmune diseases2.          
 Interest in these disorders has increased recently for two reasons. 
 1.  Immune system is involved in normal pregnancy and abnormal 
immune activation may give clues regarding the adverse outcome in 
patients with fetal losses.  
 2. Recurrent abortions and its association with certain 
autoantibodies (the antiphospholipid antibodies)  could explain the cause 
for poor outcomes in patients with previously unexplained complications. 
 Most autoimmune disorders are so uncommon that only few 
prospective studies exist to provide accurate information for counselling   
patients about the risks, outcomes, and appropriate therapies. 
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 1.5.2 Primary and secondary Autoantibodies 
 The antibodies which have  direct casual relationship for the 
development of diseases are called 1º autoantibodies and which are not 
involved are called 2º  autoantibodies.These  2º  autoantibodies are 
important because, they are necessary for diagnosis and classification of 
the clinical conditions5.        
1.5.3Autoantibodies associated with recurrent pregnancy loss 
         Different types of autoantibodies are responsible for poor 
gestational outcomes which includes- Antiphospholipid antibodies, anti-β 
2 glycoprotein I, antibodies directed against nuclear antigens, anti-
thyroglobulin antibodies, anti-laminin, antiprothrombin antibodies(aPTs), 
anti-sacchromyces cervisiae antibodies6.  
1.Antinuclear antibodies 
         These are antibodies directed against self, which binds and destroys 
the nucleus of mammalian cells6. Autoantibodies are important for 
protein synthesis and regulation of cell cycle, which is a factor for normal 
cell activity2.  Low levels of these antibodies may be seen in normal 
individuals and it could also be seen in higher frequency in normal 
elderly population.An increase in titre is seen in patients with connective 
tissue disorders4.  
 Antibodies directed against nuclear proteins interfere with the 
formation and maturation of placenta and may lead to early fetal loss.The 
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complex formed by histone proteins and deoxyribonucleic acid induces 
tissue development. Formation of antibodies against these histone 
proteins may lead to activation of autoimmune process in mother, but by 
which it leads to recurrent gestational loss is unknown. 
 All forms of cells of fetal origin can cross placenta, during normal 
gestation and reach the maternal circulation and tissues, where they 
remain for long time even after delivery. This is called fetal 
microchimerism11.Nelson formulated that this fetal microchimerism is the 
key factor for the development of autoimmune disorders, particularly 
antinuclear antibodies. 
 This hypothesis is strengthened by the higher number of  these 
cases among females, and it peaks after gestational periods; its parallel 
reaction of chronic graft versus host disease to some self-reactive 
disorders. 
Effects of Antinuclear antibodies on pregnancy 
         Antinuclear antibodies cause inflammatory effects in the uterus 
thereby it creates an environment which does not allow the adhesion of 
embryo. Maternal immune cells misinterpret the cells of fetal origin as 
malignant cells and react against them. These patients with dysregulated 
immune system may be affected by infertility, endometrial hyperplasia, 
recurrent fetal wastage because higher titres of antinuclear antibodies in 
their circulation12. Combination of antiphospholipid antibodies and 
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antinuclear antibodies have adverse effect on the conceptual product, in 
contrary to anti-thyroid antibodies.Presence of this antibodies will not 
have any direct toxic effect on embryo, but it can lead to adverse 
gestational outcome.  
2.Antiphospholipid antibodies 
 Phospholipid molecules are normal components of cell membranes 
and they  hold the dividing cells together. These molecules are essential 
for development of placenta. Anti-phospholipid antibodies react with 
negatively charged phospholipids, which includes phosphatidyl serine 
and cardiolipin.  
 These autaoantibodies are associated with various systemic 
manifestations- cerebrovascular accidents,embolic manifestations of 
lungs, deep vein thrombosis etc13. In pregnancy these antibodies may 
react against the trophoblast resulting in sub placental clots and interfere 
with implantation and subsequently cause  defective  placentation. 
Necrotising decidual vascular lesions are seen in placenta. Thrombosis 
occurs in all trimester of pregnancy resulting in complications such as 
spontaneous abortions and intra-uterine growth retardation13. 
3. Antithyroid antibodies 
 Autoantibodies to thyroid are considered independent risk factors 
during gestational period.Euthyroid women with consecutive abortions 
have raised levels of antibodies against thyroglobulin or thyroid 
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peroxidase.These thyroid antibodies could be a part of generalised 
autoimmune reaction or direct toxic effect of antithyroid antibodies on 
developing embryo.Nearly one-fifth of healthy pregnant women and one-
fourth of women with recurrent fetal loss have autoantibodies to 
thyroid14,15. 
4. Anti-neutrophils cytoplasmic antigens(ANCA)16 
 Anti Neutrophils Cytoplasmic antigens also play a role in  
recurrent pregnancy loss. Primed neutrophils adhere to susceptible 
endothelium and ANCA antibodies interact with the ANCA antigens,  
which results in neutrophil activation. The ANCA-activated neutrophils 
release factors  thereby  damaging the endothelium and activating  
alternative complement pathway with the generation of the powerful 
neutrophil chemoattractant   complement factor 5a. 
     Complement factor 5a and the neutrophil complement factor 5a 
receptor  may compose an amplification loop for ANCA-mediated 
neutrophil activation.16 Complement mediated activation amplifies 
neutrophil influx and this activation result in severe necrotizing 
inflammation of the  placenta and blood vessel resulting in placental 
infarction and its consequences. 
 Autoantibodies are involved both  in disease pathogenesis, and 
diagnosis.Low titre autoantibodies are present in every 1 in 4 persons, so  
when diagnosing these diseases, the test used must be highly specific, 
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excluding false positives.Enumerous laboratory methods are in use, and 
newer  diagnostic tools are upcoming for early diagnosis. 
1.6Anti-nuclear antibodies have been categorised into two main 
groups 
1.6.1 Autoantibodies to DNA and Histones 
 These are antibodies directed against single and double standed 
DNA protein and histone nuclear protein.Systemic Lupus Erythematosus 
is confirmed by the presence of antibodies against double-stranded  
deoxyribonucleic acid.It is a more specific marker for this disease.The 
drug induced lupus is diagnosed by the presence of anti-histone 
antibodies17,18.            
1.6.2 Autoantibodies to extractable nuclear antigens(ENA) 
 Antibodies may be directed against the nuclear proteins which are 
extracted from the nuclei by saline wash19.Anti-smith antibodies was the 
first ENA discovered in 1966, which is a specific marker for lupus.Other 
sub-types of ENA includes ribonucleoprotein, Scl-70, Jo-1 and PM120,21.  
The sensitivity  and specificity of various autoantibodies  varies 
depending upon the type of autoimmune disorder. 
          Various types of antinuclear antibodies can be identified by IFAT 
techniques. Samples from person with generalized self-reactive disorder 
may have more than one antibodies in high titres at the same point of time 
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1.7 Techniques for ANA detection 
1.7.1 Indirect Immunofluorescence 
 Indirect Immunofluorescence  continues to be a basic technique in 
autoimmunity studies. Self reacting antibodies gives specific images 
which are called fluorescent patterns22.This gives clue regarding the 
rheumatological disorder.This method detects true positive at a higher 
rate, but false positive reaction in few cases are inevitable.Autoantibodies 
level rise when patient has active disease and is seldom detected  when 
patient is at remission.Wide variablity of results, high inter-personal 
variations and semi-quantitative results are main drawbacks, yet it 
remains as a indispensable technique in detection of autoimmune 
disorders4. 
Normal titer ranges for antinuclear antibodies is age-dependent 
 1st and 2nd decade of life: less than  1in 20  
 2nd to 6th decade:  less than 1 in 40  
 7th decade and older: less than 1 in 80  
 The pattern of immunofluorescent staining should be reported 
along with the titer. 
•  In homogeneous staining, nucleus is evenly stained.It indicates 
antibodies to histones and deoxyribonucleoproteins. 
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• In speckled pattern, fine to coarse staining of nuclear material 
occurs.It indicates autoantibodies to Smith antigen, 
ribonucleoproteins etc. 
•  In peripheral staining pattern, nuclear lamina or pores are 
stained.It indicates double-stranded (ds) DNA, rheumatoid factor, 
and antiphospholipid. 
•  In nucleolar staining,nucleoli appears stained as large particles 
within nucleus. This pattern is associated with scleroderma and 
Sjogren’s syndrome. 
•  In centromere pattern,numerous scattered particles are seen, 
indicative of a systemic sclerosis variant known as CREST 
syndrome.  
 95-100% of patients with Lupus shows antinuclear antibodies 
positivity. 65-90%  in patients with Scleroderma,50-60% in Sjogren 
syndrome,25-30% in rheumatoid arthritis22.Samples which gives positive 
result, should be confirmed by other specific methods. 
1.7.2 ELISA 
 ELISA is  also used for diagnosis of autoantibodies.Some kits 
contain only few autoantigens while others includes whole extracts4.This 
test can be used to screen large population, because it is less labour 
intensive.It can be automated, but to standardise a kit, large number of 
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samples both from community and persons with rheumatological 
disorders have to be done23. 
 A positive  result for ANA  from diagnostic tests along with signs 
and symptoms is diagnostic of rheumatological disorders.Since different 
autoantibodies are associated with one or more disease, a step-wise 
approach has to be followed. Screening of samples by indirect 
immunofluorescence  or enzyme immunoassays and if the results are 
positive, more specific test are done to confirm clinical diagnosis.  
1.7.3 Techniques used for detection of specific ANA4 
 The other techniques used for detection of specific-ANA includes 
Crithidia luciliae Immunofluorescence(CLIF), Farr assay (radio-labelled 
assay), Counter current immunoelectrophoresis(CIE), Passive 
haemagglutination assay(PHA), Western blot,Dot blot, Line blot 
Immunoassay, Multiplex Immunoassay(MIA),  Flowcytometry, Antigen 
microarray4. 
 CLIF assay 
 CLIF assay is an immunofluorescence test, by using a 
trypanosome. This test has high sensitivity, and is easy to perform. There 
is no  interference with antibodies to single-stranded DNA.It helps in 
identifying various antibodies classes24. 
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 Farr assay 
       This method is also used to identify double-stranded DNA, but this 
method is technically challenging and involves use of radioactive-
isotopes, so it is not used in most laboratories25. 
Detection of autoantibodies  using gel precipitation assays 
 Double Immunodiffusion 
 Double immunodiffusion, detects multiple antibodies at a time, is 
cost-effective  with high specificity.This method detects true positives at 
a lower rate, subjective interpretation varies from person to person, need 
for large volume of prototype sera4. 
 Counter immunoelectrophoresis 
 Counter immunoelectrophoresis is also a cost-effective procedure, 
with high specificity, detects multiple antibodies simultaneously, but this 
test also detects true positives at a lower rate, need for subjective 
interpretation. 
 Passive haemagglutination 
 Passive haemagglutination assay is a semiquantitative method with 
high specificity,but it is a time consuming procedure and needs purified 
antigen4. 
  Western blot 
 Western blot is more sensitive than, double immunodiffusion and 
counter immunoelectrophoresis, and has high specificity, but it is time 
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consuming and expensive, hence it is  used in few  diagnostic centres for 
confirmation of autoantibodies4,22.  
 Line immunoassay 
 Line immunoassay is a qualitative assay.This method is technically 
easier, with results available in 30 minutes. This method detects true 
positives at a higher rate and excludes false positives considerably,  but 
distinction between certain antibodies(Sm/RNP) are difficult29,30. 
 Multiplex Immunoassay 
 Multiple Immunoassay,detects multiple antibodies simultaneously. 
Quantification  of antigen-antibody reaction possible31,32. This method is 
more efficient and technically  simpler than immunofluorescence, 
decreases the rate of false positives, removes subjective error but it is 
very expensive procedure4. 
 Flow cytometry 
 Flow cytometry gives quantitative results.It is a cost-effective 
procedure and fully automated.It detects true positives at a higher rate  
but the major drawback is, it provides single result at a time4. 
 Microarray 
 Microarray is a nanotechnology technique  that allows 
simultaneous analysis of thousands of molecular parameters.Complete 
automation is  possible, with high sensitivity and specificity but these 
arrays have not been commercialised4,28. 
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 1.7.4 Treatment options 
 Drugs commonly used includes aspirin, low molecular weight 
heparin, prednisone. Other options includes hydroxychloroquine, 
azathioprine. Recent research is on the usage of intravenous 
immunoglobulinG, paternal lymphocyte therapy, vitamin D3 analogues, 
Phosphodiesterase inhibitors- like pentoxiphyline5.          
 Thus it is predicted that autoantibodies, represent an 
epiphenomenon of immune reaction leading to miscarriages.These 
autoantibodies may be markers of polyclonal B cell activation or an 
underlying T cell defect which is related to infertility and pregnancy 
loss.When more number of  peptides and antigens are involved, the 
immune dysregulation becomes stronger and rejection of fetus takes 
place. 
 Thus Antinuclear antibodies are found to be associated as a result 
of secondary autoimmune  phenomenon in recurrent spontaneous 
abortion, and their early diagnosis aids to give a better prognosis at an 
early stage of their reproductive lives, by optimising therapy regarding 
their clinical condition.  
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2. AIM AND OBJECTIVES 
 
• To  find out  the prevalence of antinuclear antibodies in  pregnant 
women with  bad obstetric history against healthy multiparous 
women in and around  Tirunelveli  district. 
• To evaluate the utility of  Indirect immunofluorescence using   
HEp-2 cells in the diagnosis of autoantibodies(Anti Nuclear 
Antibodies). 
• To compare the efficacy of immunoflorescence test and ELISA for 
diagnosis and interpretation of  pregnant women with bad obstetric 
history. 
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3. REVIEW OF LITERATURE 
 The autoimmune disorders tend to be common in European and 
American nations. This might not be true, because in third world nations, 
like India there are inadequate data. Moreover many cases are 
undiagnosed because of lack of proper diagnostic facilities. Recent 
studies done in near past, has found that immunologic association exist 
between mother and subsequent generations, that plays a role in 
uncomplicated gestation.If abnormal maternal immune activation takes 
place,during antenatal period,it leads to miscarriages. 
 Autoimmune diseases occur in less than five percentage of 
population, as a combination of genetic and environmental factors. 
Abnormal immune response initiated to self antigens, can cause self-
reactive phenomenon, that could be picked up by serological methods 
Autoantibodies  persist in human body for  years together and  circulate 
in blood, as  a indicator of a previous self-reactive phenomenon, but their 
mere existence alone,  is not a marker  of active disease. 
 There are enumerous studies in literature which tried to establish a 
causative relationship between specific autoantibodies associated with 
pregnancy loss. Antinuclear antibodies (ANA) are a combination of 
antibodies directed against nuclear and cytoplasmic antigens. They are 
pivotal for protein synthesis and regulation of cell-cycle, which is a key 
factor for normal cell activity.Titres of less than one in eighty dilutions 
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may present in one-third of sexually active females, and  their 
significance is  unknown2.(ASRM guidelines 2008). 
3.1.1ANA prevalence-global scenario  
 Prevalence data available from 24 countries, suggest that 
autoimmune disease occurs within 30—50/100,000population33, of which 
more than three-fourth’s are females. It is the  third most common cause 
of fatality in women below 7th decade, next to malignancies and cardio-
vascular disorders.(American Autoimmune Related Disease Association 
2011). Women are more commonly affected by autoimmune disorder in 
comparison to males (2.7 :1). 
 A  study done by  Hayashi 34 from 2181 residents of a Japanese 
town to find out the presence of different patterns of antinuclear 
antibodies. Persons with  seropositivity in IFAT  were tested by enzyme 
linked immunoassays. There they found that females were having more 
reactive antibodies when compared to males. Among 566 IF-ANA-
positive individuals, 100 individuals were found to have 114 disease-
specific autoantibodies. Of the 60 individuals, positive for disease-
specific antibodies directed against nuclear antigens,one-third   showed 
disease manifestation and more than half of the patients were 
asymptomatic. 
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 Four Thousand seventy four individuals from the  year 1999-2004 
were screened  to detect the different types of autoantibodies, by Satoh et 
al35.Autoantibodies to nuclear antigens was assessed by indirect 
immunofluorescence. The ANA positivity among US population of 
individuals ages 12 years and older was 13.8%, and it  increases as age 
advances,(P=0.01), and more common in females when compared to 
males(17.8% versus 9.6%).  This ratio peaks at 5th decade. It is less 
common in overweight and obese individuals (age-adjusted POR 0.74) 
than in persons of normal weight. 
 C J Edwards36 in Britain included  668 men, 666 women for a 
cohort study. Antibody to nuclear antigen was measured using Enzyme 
Immunoassay and confirmed using immunofluorescence.Seropositivity of 
antinuclear antibodies was present in 10.9% of males and  12.2% of  
females.  
3.1.2 ANA  prevalence in Indian population 
 An extrapolated prevalence of autoimmune disease in India is 
around 33million33. In developing countries like India there  is repeated 
contacts with micro-organisms in  early life which may increase the risk 
of development of antibodies directed against nuclear antigens in their  
adult life and also it showed that past infection by some specific 
organsims like mumps and rubella, may predispose the formation of 
autoantibodies in their adult life.  
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 Ranjana et al37 in Chandigarh,have done a retrospective study 
(1996-2006) by using IFAT reactive cases. The sample size was 36,310. 
The positive rate for antinuclear antibodies was 12.3%.An annual study 
(2006-2007), conducted on 3,435 suspected patients with rheumatological 
disorders, and the positive rate was 18.9%.  Among them, four-fifth  of 
the patients were adults. Female-to-male ratio of 3:1 was reported in this 
study. 
3.1.3 ANA prevalence in South Indian population  
 A study conducted by Lingaraj Jeyalakshmi38 in Bangalore to 
detect antinuclear antibodies and various other autoantibodies and to 
analyse these variations in different age groups. The total sample size  
was 150, with individuals from 2nd and 3rd decade in first group, 4th and 
5th decade in second group  and  persons in 6th and above decade in third 
group. Subjects were selected from  health camps in and around South 
Indian city.  Antibodies to nuclear antigens were estimated by indirect 
immunofluorescence method. Increased seropositivity of  antinuclear 
antibodies  and other autoantibodies were noted in all three groups of 
individuals. 
3.2 Risk factors  for development of autoimmune diseases 
3.2.1 ANA prevalence in accordance with age 
 The autoimmune diseases can be triggered by chronic stress, 
excessive physical activity. Persistent, low level inflammation paves the 
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way, for chronic autoimmune diseases in later life. Persistent 
inflammation is probably, the reason why men and women around age of 
forty start experiencing autoimmune diseases. 
 1. ANA prevalence among paediatric population 
 Peter N Mallelson39, in UK evaluated around thousand paediatric 
patients and   found that autoantibodies were prevalent in childhood 
populations, with 135 children, living with rheumatological disorder. 
 2. ANA in reproductive age group women 
 O Yaddin40, in his study screened 506 healthy women  and 60 
women of child-bearing age for antinuclear antibodies. After five year 
follow-up, 57 of these 60 women were found to have autoantibodies to a 
variety of autoantigens. Seven of the women had some symptoms that 
could be associated with the presence of the antibodies, so they pointed 
the fact that in normal subjects(women aged 22-44 years) high titres of 
natural autoantibodies are present. They should be followed for a period 
of atleast 5 years to see if they were at a  high risk of developing an overt 
autoimmune condition. 
 3. ANA prevalence among elderly population 
 A study conducted by Juby41 on 399 elderly patients in comparison 
with 250 healthy adults by measuring various autoantibodies, suggested 
that the presence  of antibodies directed against nuclear proteins  in 
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elderly patients with chronic illness and connective tissue disorders rather 
than healthy adults. 
3.2.2ANA prevalence in accordance with sex 
 Among  patients with connective tissue disorders, more than three-
fourth were females. The reason is unknown, probably because of 
fluctuating serum hormonal level and predominant immune response by 
T-helper 2 cells. 
 Women have a robust immune system as compared to men; and it 
acts as a double edged sword, protecting them from diseases and 
attacking them to cause diseases. Females are more prone to urinary tract 
infections, menstrual periods, pregnancy and suffer from stress,  all of 
which trigger autoimmune diseases. Men, around the age of forty, start to 
get autoimmune diseases, due to declining testosterone levels42. 
 Rus V43 in Denmark  have  found  fourteen fold higher  positivity 
in females in compared to males.  
 In Kulalampur, MR Azizah44 screened serum samples from 93 
blood donors. Antibodies to nuclear antigens were assayed by  
immofluorescence method using human epithelioma cells as substrate. 
Raised titres were found in 2/19 (10.5%) females and 4/74 (5.40/0) males 
(p >0.05). 
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 In Brazil, Fernanderz sav et al45screened samples from 500  blood 
donors and found that the female donors had high risk  of seropositivity 
for antibodies directed against nuclear antigens. 
 A study conducted by Hayashi34 in Japan  for disease-specific  
antibodies directed against nuclear antigens (ANAs) from 2181 residents,  
inferred that  antinuclear antibodies positivity were higher  among 
females. 
3.2.3 ANA prevalence among various racial groups 
 African American, American Indian, or Latino people  are more 
likely than Caucasians  to develop autoimmune disorders. 
 A study done by Cacciplaglia46, compared migrants to Italy and 
native Caucasian population. Antibodies directed against nuclear proteins 
were assessed  by fluorescent  microscopy. They  found  that the migrants 
were having high positive rates for antibodies against nuclear 
proteins(23.7% vs 8.3%). 
3.2.4 Familial predisposition to autoimmunity  
 Studies have shown that the tendency to develop autoimmune 
disorders can be inherited.The genes which plays role in the development 
of autoimmune disorders, can be transmitted vertically and each abnormal 
genes may give rise to different types of presentations.            
 Huang C M47 in Taiwan  studied family members and close 
relatives of different rheumatological disorder and found that there was 
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higher rates of positivity  among 2nd and 3rd  degree relatives  of patients 
with Lupus when compared to first degree ones.  
 Eaton et al48 studied 31 types of connective tissue disorders and 
found that the disease have higher preponderance in family members. 
3.3 ANA prevalence among blood donors, hospital personnel 
 A study done in Mexico by Marin49, evaluated three groups of 
persons- blood donors, persons working in hospital, and relatives of 
patients with rheumatological disease. 
 The study population were healthy during the conduct of study. 
Among 304 individuals screened, 165 were found to have antibodies 
directed against nuclear antigens.Hospital personnel and relatives of 
patients with rheumatolgical disorders had higher positive rates, and 
speckled pattern was the  most common finding among them.  
 Serum of 500 adult blood donors  were tested for the presence of 
autoantibodies by Fernanderz sav et al45. Antibodies directed against 
nuclear proteins were detected in 22.6% of the sera.  
3.4 Antinuclear antibodies prevalence among pregnant women 
 Some of the connective tissue disorders tends to rise during 
reproductive age groups. During  gestational period there will be a 
exchange of cells between mother and the developing conceptus, which 
may sustain in their circulation even after delivery5.This may lead to the 
development of autoimmune disorder in future .Only few prospective 
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studies exist to provide accurate information for counselling patients 
about the risks, outcomes, and appropriate therapies pertinent to 
pregnancy. 
 Farnam J50 screened 214 antenatal mothers with 50 controls to 
determine ANA positivity.23 antenatal women were found to possess 
seropositivity to antibodies directed against nuclear antigens  while only 
one patient in control group tested positive. In the antenatal 
mothers,13.4% of  mothers belonged to late gestational period and 9.2% 
of mothers in mid gestational period. Antibodies directed against 
deoxyribonucleic acid was present in 2 patients. 
 Rosenberg51 evaluated early, mid, and late gestational serum 
samples from 100 healthy pregnant women, umbilical cord serum 
samples from each delivery, and for comparison, sera from 76 non-
pregnant control subjects were assayed by immunofluorescence  by 
microscopy for the presence of antibody to HEp- 2 cell nuclei at titers of 
greater than or equal to 1 in 80.  
 At serum dilutions of 1 in 80, the numbers of samples positive in 
the early, mid and late gestations and cord sera were 18, 21, 21, and 15, 
respectively. At serum dilutions of 1 in 160, the numbers of sera positive 
for antinuclear antibodies in each trimester and  in cord sera were 9, 12, 
9, and 8, respectively. 
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 Patton52 in Italy screened samples from 136 women (84 pregnant 
and 52 nonpregnant) for antibodies directed against nuclear antigens, 
smooth muscle antigens, by indirect immunofluorescent microscopy. 
Immunofluorescence assays were considered positive if antibodies were 
detected at a  dilution of serum 1 in 20. The mean ages of the two groups 
were 32 and 26 years, respectively. Autoantibodies did not differ in the 
study (46.2) and control groups (40.5).  
3.5.1 Antinuclear antibodies prevalence among women with  Bad 
Obstetric History 
 Garcia et al53 compared the prevalence of  antibodies directed 
against nuclear antigens in the sera from patients with more than 3 
miscarriages to that of women with normal gestation. Antibodies  
directed against nuclear antigens were more prevalent in patients with   
more than 3 miscarriages(30%) when compared to women with normal 
gestation (6.6%).   
 Xu L54 in Japan compared  four groups of women to study ANA 
prevalence among them. Group A consisted of 30 patients with a history 
of unexplained fetal losses. Group B consisted of 30 women with 
"explained" fetal losses (e.g., uterine septum or luteal phase defect). 
Group C consisted of 61 healthy pregnant women. Group D involved 61 
healthy non-pregnant women of reproductive age.  
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 In groups A and B, 40% and 53.3% of the respective patients had 
antinuclear antibody titers greater than or equal to 1 in 40 dilutions. In 
groups C and D the frequencies of positive antinuclear antibody titers 
were 8.2% and 5.6%, respectively. 
  Nakatsuka et al55 in Japan, studied the efficacy of examining 
antinuclear antibody (ANA) as a screening test to detect subclinical 
immune disorders in infertility and sterility. ANA was measured in 116 
unexplained infertile or sterile patients.  
 The ANA positive rate was 43.5% in group A (habitual abortion, n 
= 23), 38.1% in group B (consecutive miscarriages, n = 21), 30.0% in 
group C (one miscarriage, n = 10), 16.7% in group D (one or more 
deliveries n = 12) 22.0% in group E (primary sterility, n = 50), and 22.4% 
in the control group (n = 54). The positive rate for all the infertile patients 
(group A+B) was 40.9% and significantly higher than that in for the 
control group (p < 0.05). 
 Bahar et al56 conducted a controlled study on 103 patients with 
unexplained recurrent spontaneous abortions for frequency of  positive 
test for anticardiolpin  and antinuclear antibodies. The frequency of 
positive test for antibodies directed against nuclear antigens was 13.6% in 
persons with recurrent spontaneous abortions compared to 1.2% in 
control population. No difference was found between first and second 
trimester aborters  in frequency of positive test for either ACA or ANA. 
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 Malinowski57, in Lodz, compared the frequency of  low-level 
antinuclear antibody titers in  68 women with bad obstetric history (group 
A) to that in 35 with explained repeated pregnancy losses (group B) and 
44 healthy pregnant (group C), and 36 healthy non-pregnant women 
(group D). 
 The frequency of antinuclear antibodies positivity in a dilution of 1 
in 40 or higher was 51.5% in group A, 34.3% in group B, 6.8% in group 
C and 5.6% in group D. 
 A study  was done by Remaind60 in Argentina in 108 females with  
bad obstetric history against control group of 392 women from general  
population. They reported 40.7% positivity in women with bad obstetric 
history and 14.8% positivity in control sera. Antibodies directed against 
nuclear antigens was the most common association. 
 Eroglu61 analyzed  the presence of antibodies to phospholipid and 
nuclear antigens in   72 women with a history of recurrent fetal wastage. 
An indirect immunofluorescent  antinuclear test was performed. Nine 
women (13.2%) had low levels of antinuclear antibodies, none of which 
were specific. 
 In a study  conducted in Argentine women62 with early gestational 
loss and fertile women, no significant difference  in antinuclear 
antibodies positivity could be attributed to either of the groups. 
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 Ruiz JE63 in his study, tested Colombian women with poor obstetric 
performance to antiphospholipid antibodies and antibodies directed 
against nuclear proteins. Sixty-eight non-pregnant and 25 pregnant 
women with poor obstetric  performance  included in the study group was 
compared with  56 healthy pregnant and non-pregnant females. There 
was no difference in the seropositivity of antinuclear antibodies in either 
group. 
 Bahar et al56 found that less positivity  rate for patients with  
recurrent spontaneous abortions(8%) in comparison to normal 
multiparous women (10%), in Kuwait population using 
immunofluorescence by microscopy. 
 Petri et al64,  investigated ANA prevalence in women with three 
pregnancy loss was around 16% when compared to healthy women it was 
around 20% using indirect immunofluorescence, from a population of 60 
women in each group. 
3.5.2 Antinuclear antibodies association among BOH patients in 
Indian scenario 
 U.Shankarakumar7  in Mumbai, studied Fifty patients with sub-
fertility or infertility along with 50 healthy antenatal women  for various 
auto-antibodies such as ANA, anti-dsDNA, ANCA,AECA using 
immunofluorescence and ELISA. 34% of study population tested positive 
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for autoantibodies.Antinuclear antibodies was present in 12% of patients 
with infertility compared to 2% among controls. 
 Usha13 in Varanasi, studied cohort of 28 female patients with  
recurrent abortions, which included 8 primary aborters and 20 secondary 
aborters. Twenty normal fertile female controls were studies for IgG 
anticardiolipin antibodies by ELISA and ANA by HEp-2 cell nuclei using 
indirect immunofluorescence methods. Secondary aborters had more 
increased frequency of anticardiolipin antibody (35%) as compared to 
primary aborters (12.5%). 
3.6 ANA detection by Indirect Immunofluorescence 
3.6.1 ANA results by titre-wise distribution  
 Rosenberg51 evaluated  early, mid and late gestational serum 
samples from 100 healthy pregnant women, and76 non-pregnant control 
subjects  assayed by indirect immunofluorescence for the presence of 
antibody to HEp 2 cell nuclei at titers of greater than or equal to 1 in 80 
dilutions.  
 At serum dilutions of 1 in 80, the numbers of samples positive in 
early, mid, late gestation, and cord sera were 18, 21, 21, and 15, 
respectively. At serum dilutions of 1 in 160, the numbers of sera positive 
for antinuclear antibodies in each trimester and in cord sera were 9, 12, 9, 
and 8, respectively. 
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 Harger 65 in Pennyslavia, USA compared a group of 277 women 
with recurrent pregnancy loss to that in 299 pregnant controls and 119 
non-pregnant controls. The frequency of positive antinuclear antibody 
tests at a titer of 1 in 40 or higher was 16.3% in cases, 16.6% in pregnant 
controls, and 16.8% in non-pregnant controls. Increasing the critical titer 
to 1 in 80, however, led to a statistically significant difference between 
cases (6.9%) and controls respectively. 
 A study done in Brazil45 in 500 blood donors included in the 
sample, 113 were positive for ANA,  prevalence of 22.6% were observed. 
Among the donors who presented ANA+, 73(64.6%) had a titer of 1 in 
40, 23 (20.4%) a titer of 1 in 80, 10 (8.8%) a titer of 1 in 160, and 7 
(6.2%) a titer equal or higher than 1 in 320. 
 Hayashi N34 investigated 2181 residents in Japan, and antinuclear 
antibodies positivity rates were 26% and 9.5% at dilutions of 1 in 40 and 
1 in 160  respectively.  
 In Mexican population, Marin49 studied 304 individuals, of which  
antibodies directed to nuclear antigens was detected in 165 serum 
samples (54.3%). The most common titre was 1 in 40 (35.4%), followed 
by 1 in 80 (13.4%), 1 in 160 (3.2%), and 1 in 320 (1.3%). 
3.6.2 Evaluation of ANA detection by various HEp-2 cell pattern 
 The families of 65 patients with systemic sclerosis were 
investigated Maddison66.The patients were subjected to 
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immunofluorescence technique using human epithelioma substrate. 
Among 217 individuals  who participated in test, 58(27%) had 
antinuclear antibodies.The most common pattern being speckled(42 
persons),  followed by nucleolar(13 persons), homogeneous(2 persons) 
and centromere pattern in one person.   
 In India, Chopra67 detected ANA  from sera and filter paper blood 
clots of 21 patients with proven connective tissue disorder  using indirect 
immuno-enzyme method.The most frequent ANA patterns was 
homogenous, speckled, and centromere. 
 I E Afmann68 in South Africa, conducted a study which consisted 
of 46 patients who tested positive for antibodies against nuclear antigens. 
Among 46 women, 28 had an antinuclear pattern, 13 an anti-cytoplasmic 
pattern and 5 anti-nucleolar. 
 Total of 304 individuals, were screened by Marin49, fluorescence 
was detected in 165 serum samples (54.3%). The most frequent pattern 
was  speckled (50.3%).  
3.7 Comparison of ANA detection by  IFAT and ELISA 
 In Japan  Kumagai69 tried to differentiate 258 connective tissue 
disease (CTD) patients (except rheumatoid arthritis) from 257 healthy 
subjects between Enzyme Linked Immunosorbent assay and indirect 
immunofluorescence by Microscopy. The true positives and true 
negatives of Enzyme Linked Immunosorbent  assay  were 84% and 94%, 
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respectively, while those of IF-ANA at a titre of 1 in 160 were 81% and 
87%. The receiver operating characteristic (ROC) analysis  concluded 
that Enzyme Linked Immunosorbent assay   was better than IF-ANA. 
 Divate et al70  have studied  samples from 96 patients with 
connective tissue disorders, by   Enzyme Linked Immunosorbent assay of 
which  53  samples were positive and 43 were negative for 
immunofluorescence. The sensitivity, specificity, predictive values for 
positive(PPV) and negatives(NPV) of  ELISA were 90.7%, 85.7%, 
89.1%, 87.8% respectively.  
 In Spain, Gonzalez71, investigated serum samples from 74 healthy 
individuals, 119 patients with defined systemic autoimmune diseases, 26 
patients with other autoimmune diseases, and to which 490 routine 
samples were  also analysed by ELISA.  
 For systemic lupus erythematosus (SLE) patients, the COBAS-
ANA(ELISA kit) best efficiency was obtained with a cut-off of 0.9, with 
a sensitivity of 97% and a specificity of 88%, whereas the best IFA-ANA 
efficiency was obtained with  1 in 80 dilution, giving a sensitivity of 90% 
and a specificity of 99%. There were no differences between areas under 
receiver operating characteristic curves for  two methods. For other 
systemic and non-systemic autoimmune diseases sensitivity and 
specificity of COBAS-ANA were similar or higher than that of 1 in 160 
IFA-ANA titer. 
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         Tonuttia et al72 in Italy, studied the efficacy of five  types of 
ELISA kits  in comparison with imunofluorescence  to identify antibodies 
directed against nuclear proteins. The seropositivity of 
immunofluorescence technique was 92%, whereas  five ELISA kits  
showed positive results which ranged from, 74 to 94%. ELISA kits were 
able to identify   all antibodies which produces homogeneous and 
speckled  pattern, in contrary to nucleolar  pattern. 
 Paz73 in Israel,  compared Enzyme Linked Immunosorbent Assay 
with  IFAT method, from eighty five  patients with SLE and 51 healthy 
volunteers. The samples were tested by the above  two methods at 1 in 40 
and 1 in 160 dilutions.Those who were positive for indirect 
immunofluorescence showed better reactivity for Enzyme Immunoassay 
compared to those who had negative results. 
 Enzyme Immunoassay was compared to indirect 
immunofluorescence by Op De Beecke74(2011) to identify antibodies 
directed against nuclear proteins in various rheumatological disorders.The 
sensitivity of EliA CTD Screen for systemic lupus erythematosus, 
systemic sclerosis, primary Sjögren's syndrome, mixed connective tissue 
disease, and inflammatory myopathy was 74%, 72%, 89%, 100%, and 
39%, respectively. 
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  Dipti75 in Bangladesh evaluated immunofluorescence method and 
enzyme immunoassay  in 40  patients, of  which 20 had Lupus since 
younger age, and 20 patients had other autoimmune disorders excluding 
Lupus.The antinuclear antibodies positivity rate was 100% by IFAT and 
55% by enzyme immunoassay in patients with Lupus since younger 
age.Immunofluorescence have more diagnostic capacity than enzyme 
immunoassay in antinuclear antibodies positivity. 
3.8 Techniques used for detection of specific ANA 
 Crithidia luciliae assay 
 Thirty four systemic lupus erythematosus patients  were screened 
by Sommerfield76 using radio-labelled assay, passive haemagglutination, 
and Crithidia Luciliae  assay.Among these methods, results of Farr assay 
and Crithidia luciliae assay were similar, while the findings in 
haemagglutination method were quite dissimilar from the other two 
methods. 
 Indirect Immunoenzyme method 
 Chopra A67 compared simple Indirect immunoenzyme with the 
help of light microscope with indirect immunofluorescence. In his  study, 
he identified antinuclear antibodies  from serum samples and  filter paper 
blood clots(FPBC) of  patients who were diagnosed with proven 
rheumatolgical disorder using IIE.Both FPBC and serum samples were 
collected from 10 patients.The results of two methods was similar.ANA 
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patterns(homogenous, speckled, centromere) from both FPBC elutes and 
serum are comparable.           
 Passive haemagglutination 
           The results of passive haemagglutination were evaluated by 
Niemhom77, with those obtained by immunofluorescence in 169 patients 
with active SLE and inactive SLE.59 sera were positive and 91 sera were 
negative by both methods. Five sera were negative by haemagglutination 
but positive by immunofluorescence. Fourteen sera with low 
haemagglutination titer were negative by immunofluorescence.  
 The correlation between the results obtained by both methods were 
highly significance with contingency coefficient of 0.61 and correlation 
coefficient between the results of 78 sera positive by both or either 
method was 0.74. 
 Line blot assay 
 Damoiseaux29  compared line immunoassay with counterimmuno 
electrophoresis   (in house CIE) and enzyme immunoassay  for the 
presence of  autoantibodies.148   patients with proven rheumatological 
disorders and 40 controls participated in the study.The true positive rate 
for line immunoassay was(17.9%) , for enzyme immunoassay (11.4%) 
and for inhouse CIE (8.3%).  
 Serum samples of patients from a random South Indian population1 
who sought medical help for rheumatic disease were subjected for ANA 
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testing by indirect immunofluorescence (IIF) method and line 
immunoassay during the study period of 27 months. Serum samples were 
initially processed for indirect immunofluorescence, and further for line 
immunoassay.  
 The antinuclear antibody indirect immunofluorescence (ANA - IIF) 
patterns obtained were projectable to visualize a certain spectrum of 
specific antibodies such as homogenous (45.5%) with dsDNA, 
nucleosomes, histones, SSA / Ro-52, RIB and RNP / Sm, speckled 
pattern (35.6%) with Sm, RNP, SSA/Ro-52, SSB, Sm and RIB; nucleolar 
pattern with Scl-70, Sm, RNP and centromere pattern with CENP-B. 
 Multiplex Immunoassay(MIA) 
 Assay specificity was evaluated by testing samples from 50 blood 
donors and 30 specimens  from samples with patients having 
cryoglobulinemia  hypergammaglobulinemia, or IgG and IgM monoclonal 
immunoglobulins, complement-associated diseases. To evaluate assay 
sensitivity,142 samples from patients with systemic rheumatic disease  
that were tested previously by routine methods. The sensitivity and 
specificity were 99.1% and 100%27,28. 
 Hayashi et al34 compared Multiplex Immunoassay and 
immunofluorescence (IF) assay in  492 persons from community and 307 
persons with autoimmune disease. The sensitivity and specificity of the 
IF method at a titre of 1 in 40 were 92% and 65%, respectively, vs 93% 
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and 79% for the MIA at a cut-off of 0.6, but  at  higher titres in IFAT and 
higher cut-off  with MIA, the results are similar to some extent.   
 Antigen Microarray 
 Microarray technology allows the simultaneous analysis of 
thousands of molecular parameters. Microarrays are made using either 
on-chip synthesis strategies or with an arrayer based on  contact-printing 
or ink-jet technology4,28.The recognition of autoantibodies may be 
achieved using fluorescence or radio-active labelling, 
chemiluminescence, mass spectrometry or electrochemical methods. 
3.9 Various treatment options  for women with RPL 
1. Aspirin/heparin therapy 
 Acetyl salicyclic acid and low dose heparin are first line drugs for 
women with RPL5.Aspirin is more preferred because it crosses placenta. 
Reznikoff- Etievant78 investigated 678 healthy patients with 
recurrent gestational loss of which 161 autoantibody-negative and 53 
autoantibody -positive women received  prednisone and aspirin and 63 
autoantibody-negative women received aspirin alone. In autoantibody-
positive patients treated with prednisone and aspirin the success rate was 
84.9% . 
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2.Prednisone 
 The mechanism action of steroids is that they suppress  the 
inflammatory process and stabilizes the cell. Out et al79(1992) found 36% 
pregnancy loss rate in patients treated with prednisone compared with 
22% pregnancy loss in patients treated with both prednisone  and anti-
coagulation therapy. 
3. Intravenous immunoglobulin (IVIg) therapy 
 The mechanism by which gammaglobulin acts is that it alters T-
cell subsets,modulates cell mediated immune response,neutralises 
cytotoxic effect of maternal immune response against fetus.It could be 
safely used in persons with side-effects to aspirin and heparin5. 
 A study done by Stricker53 to evaluate the usefulness of 
gammaglobulin in  47 women  with recurrent fetal wastage, found 75% 
successful pregnancy rate. 
 Christiansen O B80 in his study reported that patients who were 
given intravenous immunoglobulin treatment  for sub-fertility, had better 
success rate compared with placebo.  
4.  Lymphocyte immunotherapy 
 Lymphocyte immunotherapy helps to decrease  the level of 
maternal  interleukin receptors,  shift to Th-2 type immunity and causes 
suppression of natural killer cell activity5.   
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5.1a, 25 –dihydroxy-vitamin-D3 (VD3] therapy 
 Vitamin D3 acts as a immunomodulatory agent.The mechanism of 
action is not known, probably it is thought to down-regulate the 
production of T-helper cytokines. 
 Thus it is known that, changes in immune system occur during 
antenatal period.The presence of antinuclear antibodies in women is 
either an expression of subtle immune disorder or is an immunologic 
epiphenemenon is not clearly defined.On reviewing the literature, it is 
suggested that ANA detection would be of some value in identifying 
patients with these disorders, as the condition is treatable. 
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4. MATERIALS & METHODS 
4.1 Materials 
4.1.1 Study period 
 The present study was conducted from the period of August 2011 
to September 2012. The study population comprises  mainly of pregnant 
women from 19-40 years, attending Antenatal clinic and inpatients in  
Obstetrics and Gynaecology Department, Tirunelveli Medical College 
Hospital. 
4.1.2 Sample size 
 This is a case-control study comprising of equal number of cases 
and controls, each comprising 60 women of reproductive age group. 
4.1.3 Study group 
            The study population comprises of  60 pregnant women from age 
group 19-40 years 
 With history of 2 or more spontaneous abortions. 
 It also includes women with past history of still-births, intra-uterine 
death or early neonatal deaths. 
The population was carefully selected that  women in study group 
has no live issues. 
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 4.1.4 Control group 
         The control group comprises of  60 multiparous pregnant women 
from age group 19-40 years,  with no history of abortions. 
4.1.5 Exclusion criteria 
This group was carefully selected to exclude women: 
 history of  heart disease, anaemia,renal failure 
 history of Rh-incompatability 
 history of sexually transmitted diseases, or TORCH infections 
 history of uterine fibroids, endometriosis, PID, uterine 
anomalies- septate uterus, bicornuate uterus. 
4.1.6 Ethical clearance 
 Since the study involves blood samples from pregnant women, 
institutional ethical clearance was obtained. 
4.1.7  Informed Consent 
 Informed written consent was obtained from all pregnant women 
involved in the  study, both study  and control group. 
4.1.8 Questionnaire 
 Questionnaire was given to all  persons  which included details 
about, their name, age, spouse age, last menstrual period, any complaints 
like-abdominal pain, draining per vaginam, bleeding per vaginam, history 
of systemic illness, menstrual history- age at menarche, duration of 
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menstrual cycle, obstetric history- which includes their gravida, 
abortions- spontaneous or induced, nature of past delivery- full term/ pre-
term, normal vaginal delivery or Caessarean section, any contraceptive 
usage, sexually transmitted infections any, drug intake for some disease. 
4.1.9 Sample collection 
 Under strict aseptic precautions,3-5ml blood was collected from 
both study group and control group, using sterile syringe. 
 4.1.10 Separation of serum from sample 
 Blood  was collected in sterile glass tubes, and sample container 
was kept in slanting position at room temperature for 30 minutes. From 
the specimen vial, serum was transferred to sterile screw capped leak 
proof tube. 
 Lipaemic, lysed, deteriorated samples were discarded.  
4.1.11 Storage of serum 
 Serum vials were packed in a second tightly capped unbreakable 
container, surrounded by adequate packing material and stored at -20˚C  
deep freezer. 
 4.1.12 Biomedical waste management 
 As the materials handled were highly infectious, proper biomedical 
waste management was followed throughout the study. 
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4.2 Indirect Immunofluorescence Hep-2 cells (ANA-Hep-2) 
 Antibodies directed against nuclear antigens bind to the 
corrsponding antigen’s present in human epithelioma cell type-2 
substrate.Over this antigen-antibody complexes, fluorescein tagged anti-
human IgG is added,which is visualised by fluorescent microscope. 
 
4.2.1Principle of the method 
4.2.2 Composition 
A. Slides: Hep-2 cells cultured on each well. 
B. PBS(10X): Sodium phosphate 112.5mmol/L, potassium phosphate 
30mmol/L, sodium chloride 1.15mol/L, sodium azide 0.95g/L, pH 7.2 
C+. ANA-Hep-2 positive Control: Human serum containing anti-nuclear 
antibodies(ANA) homogeneous pattern, sodium azide 0.95g/L 
C-. Negative Control: human serum, sodium azide 0.95g/L 
D. IgG FITC/Evans: Goat anti-human IgG conjugated with fluorescein 
isothiocyanate(FITC), Evans blue 0.01g/L, sodium azide 0.95g/L 
E. Mounting Medium: Mowiol 12%, Glycerol 30%, Tris 20mmol/L, 
sodium azide 0.95g/L 
F.  Blotting paper 
4.2.3 Storage 
Store at 2-8˚C. 
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4.2.4  Reagent preparation 
PBS:  Reagent was diluted  1 in 10 with distilled water. 
All other reagents were provided ready to use. 
4.2.5 Additional equipment 
 Moist chamber 
 Wash tray 
 Coverslips 24*60mm 
 Fluorescence microscope equipped with a 495nm excitation filter 
and a 525nm emission filter for FITC visualisation. 
4.2.6 Samples 
 Samples were diluted one in eighty in phosphate buffer saline 
before the assay. 
 For titration of positive samples, two-fold serial dilutions starting 
1/160 in PBS were made. 
4.2.7 Procedure 
1. Reagents and samples were allowed  to come to room temperature. 
2. A drop(25µL) of diluted sample or control was placed on each 
slide(A) well, making sure  that it was completely covered(note 1). 
3. The slide were incubated for 30 minutes at room temperature(15-
30˚C) into a moist chamber. 
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4. Sample drops were drained off by gently tapping the inclined slide. 
Cross-contamination of the sera were avoided. 
5. The slide was gently rinsed with PBS. 
6. The slide was thoroughly washed by immersing in washing tray 
filled with PBS for 5minutes. PBS is changed and wash was 
repeated.  
7. The slides were carefully dried off by using the blotting paper 
provided. The substrate  was kept moist along the procedure. 
8. One drop of reagent D was placed on each well. The slide was 
incubated for 30 minutes at room temperature(15-30˚C) into a 
moist chamber. 
9. Wash (step 6) and dry (step 7). 
10. Several drops of reagent E was placed on the slide and covered 
with a cover-slip avoiding  the formation of  air-bubbles. 
4.2.8 Reading 
 The slide were examined using low power and high power of 
fluorescent microscope. 
 The slides  were  read as soon as procedure is over. 
  The area, between the centre  and  edge  were selected for 
visualising. 
  Uniform spacing between cells and nuclei  give a better picture. 
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4.2.9 Quality control 
 Positive control and negative control provided with the kit should 
be tested together with the patient samples, in order to verify the assay 
performance. 
4.2.10 Assay characteristics 
 IgG FITC/Evans and IgG FITC conjugates are valued against the 
WHO International Standard for FITC labelled sheep anti-human 
immunoglobulin. 
4.3 ELISA kit 
4.3.1  Principle of  test 
         Specific anti-nuclear antibodies(ANA) in the sample bind to the 
antigens immobilized on the microwell surface. In a second incubation, a 
conjugate of horseradish peroxidase-labeled immunoglobulins to human 
IgG binds to surface-bound antibodies. Finally, 3,3’,5,5’- 
tetramethylbenzidine(TMB) with hydrogen-peroxidase was added to each 
well as enzyme substrate and, after color development, the enzymatic 
reaction was stopped with hydrochloric acid. The yellow product formed 
was measured in terms of absorbance units at 450nm, and it is 
proportional to the amount of antibodies present in sample. 
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4.3.2 Contents and Composition 
A) Concentrated Washing Buffer,50ml 
Concentrated phosphate saline buffer, sodium azide15mmol/L 
B) Sample diluent 100ml 
Tris buffer, sodium azide 15mmol’L 
C)Positive Control 1.5ml 
Provided ready to use. Serum with ANA, sodium azide 15mmol/L 
C)Negative Control 1.5ml 
Provided ready to use. Serum free of ANA, sodium azide 15mmol/L 
CO. Cut-Off Standard 1.5ml 
Provided ready to use .Serum with ANA, sodium azide 15mmol/L 
D)Conjugate.15ml 
Horseradish peroxidase-labeled polyclonal rabbit immunoglobulins to 
human IgG 
E) Substrate.15ml 
3,3’5,5’-tetramethylbenzidine(TMB) 
F) Stop solution.15ml 
Hydrochloric acid 1.0mol/L 
G) Microplate 
         12modules of 8 wells each coated with a mixture of purified SSA 
52, SSA 60, SSB(La), Sm/RNP, RNP-70, RNP-A, RNP-C,SmBB’, SmD, 
SmE, SmF, SmG, Scl70,Jo1, dsDNA,ssDNA, polynucleosomes, 
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mononucleosomes, histone H1, histone H2A, histone H2B, histone H3, 
histone H4, PMScl-100, and centromere B. 
4.3.3. Storage 
Store at 2-8˚C. 
4.3.4 Reagents and Preparation 
Washing buffer 
  Concentrated washing Buffer was diluted with distilled water in the 
proportion 1/20and mixed throughly. About 50ml of washing buffer were 
used per strip.  
 All other reagents were provided ready to use 
4.3.5 Additional Equipment 
 Moist chamber 
 Multi-tip aspirator or automatic washing equipment for microplates 
 Microplate reader or photometer with microcuvette, with a 450+/- 
10nm filter. 
4.3.6 Samples 
 Serum or plasma were collected by standard procedures. Sample 
was diluted with 1/100 with sample diluent. Fresh sample dilutions has to 
be  used always. 
 
 
57 
 
4.3.7 Procedure 
1. All the reagents and microwells were allowed to warm up to room 
temperature. 
2. The microplate  package(M) was opened and  the required amount 
of wells were taken out. 
3. 100µL of each diluted sample, Cut-off standard(CO), Positive 
Control(C+) and Negative Control (C-) were pipetted  into 
different wells. 
4. Wells were placed in a moist chamber and incubated for 30 
minutes at room temperature. 
5. The contents were aspirated and  the well’s were washed 3 times 
with 300µL of washing buffer for atleast 10 seconds. 
6. 100µL of Conjugate(D) was pipetted into all wells. 
7. The wells were placed in the moist chamber and incubated for 
15mins at room temperature. 
8. The wells were washed as in step 5. 
9. 100µL of Substrate(E) was pipetted into all wells. 
10. The wells were placed in moist chamber and incubated for 15 
minutes at room temperature. 
11. 100 µL of stop solution was pipetted into all wells and incubated 
for 5minutes at room temperature. 
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12. The absorbance of the contents  of each well were read at 
450nm.The colour is stable for atleast 30minutes. 
4.3.8 Calculations 
 The absorbance ratio was calculated as follows:  
 
                        Absorbance ratio  =          
                                                             
 When the absorbance values obtained are over the upper limit of 
the microplate reader range, samples should be further diluted with 
Sample diluent and reassayed. 
4.3.9 Reference values 
 Samples with absorbance ratio higher than 1.2 are to be considered  
positive. 
 Samples with absorbance ratio lower than 1.0 are  to be considered 
negative. 
 Samples with absorbance ratio between 1.0 and 1.2 would be 
considered as border line and repeat testing is recommended. 
 These values were given for orientation only. It is recommended 
that each laboratory establishes its own reference values. 
 
 
A450nm  sample 
A450nm  cut-off 
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4.3.10 Quality control 
 Absorbance of positive control should be higher than 0.600. 
 Absorbance of negative control should be  lower than 0.300. 
 Cut-Off Standard should be higher than 0.300 
4.3.11 Interferences 
         Hemoglobin (1000mg/dl), bilirubin (40mg/dl) and triglyceride 
(3000mg/dl) do not interfer. Other substances and drugs may interfere. 
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5. RESULTS 
 5.1 Study group 
         A total of 120 pregnant women were included in the study.60 
pregnant women with bad obstetric history were evaluated against 60 
mutiparous women. This study was conducted for a study period of one 
year from August 2011 to September 2012. The study population mainly 
consisted of women attending antenatal clinic and inpatients in Obstetrics 
and Gynaecology Department, Tirunelveli Medical College Hospital, 
Tirunelveli. 
5.2 Statistical Analysis 
        Data regarding the cases and controls were described in terms of 
percentages. Sensitivity, specificity, positive predictive value, negative 
predictive value of ELISA  was done. The cases and controls were 
statistically analysed for significance by Chi-squared test. The Chi-
squared test was calculated for the analytic assessment by SPSS  20 
version software. The differences were considered to be statistically  
significant when the p value obtained was less than 0.05. 
 
 
 
 
 
 5.3 Result Analysis  
Age-wise distribution of 
Age(in 
yrs) No of cases
16-20 7 
21-25 13 
26-30 21 
31-35 12 
36-40 7 
Total 60 
 
 Table 1 shows the age distribution  among 
present study which shows that, women between the age group 26
comprises maximum number which includes 21 cases and 23 controls 
respectively.(fig 1). 
Age-wise distribution of cases and controls
.
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Table-1 
BOH cases  and   controls
 
Percentage 
of cases 
No of 
controls 
Percentage 
of controls
11.6 5 
21.66 14 
35 23 
20 11 
11.6 7 
100 60 
cases and controls in the 
Fig – 1 
 
21-25 26-30 31-35 36-40
13
21
12
7
14
23
11
7
No of cases
 
 
8.33 
23.33 
38.33 
18.33 
11.6 
100 
-30 
 
 ANA positivity among cases and controls
Samples 
Total 
number
Cases 
Controls 
 
 Table 2 shows distribution of ANA positivity among cases and 
controls. Among 60 women with BOH, 18 (30%) were found to be 
positive. Among controls 5(8.3%) women were positive.
ANA positivity among cases and controls
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Table - 2 
 
 
ANA positivity
number Percentage
60 18 
60 5 
(fig 2)
Fig – 2 
 
 
 
85%
15%
 
 
30 
8.3 
 
 
Cases
Controls
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Table - 3 
Age-wise distribution of BOH women with ANA positivity 
S.no 
Age in 
yrs 
No of 
samples 
tested 
ANA positive cases ANA negative cases 
Number Percentage Number Percentage 
1 16-20 7 1 5.55 6 14.28 
2 21-25 13 3 16.66 10 23.80 
3 26-30 21 8 44.44 13 30.95 
4 31-35 12 6 33.55 6 14.28 
5 36-40 7 - - 7 16.69 
 Total 60 18 100 42 100 
 
 This table shows  age-wise distribution  of BOH cases and anti-
nuclear antibodies positive among them. Of the 7 samples tested from 
age-group 16-20yrs, 1sample is positive and remaining were negative. Of 
the 13 cases tested 3 were positive and 10 were negative in the age-group 
21-25 yrs. From 26-30yrs, 21 samples were tested, of which 8 samples 
were positive and remaining 13 tested negative. Twelve individuals were 
tested from age-group 31-35 yrs,6 were positive and remaining 6 were 
negative. Among 7 cases tested from age-group 36-40 yrs, none were 
positive.(fig 3) 
         Of the total 18 cases, which were positive 8 (44.44%) women were 
in the age group 26-30, 6(33.5%) women were in the age group 31-35,3 
 (16.66%) women were in the age group 21
age group 16-20 yrs, while in women with 36
positivity 
          Of the 42 negative women with history of BOH, 6 (14.28%), 10 
(23.8%), 13 (30.95%), 6 (14.28%),7 (16.69%) were in the age
20yrs, 21-25yrs, 26-30yrs,31
age among cases is 28 years.
Age-wise distribution of BOH women with ANA positivity
 
16-20 21-
1
3
6
10
65 
-25, and 1(5.55%) was in the 
-40 yrs, none showed 
-35yrs, 36-40 yrs respectively.  The mean 
 
Fig - 3 
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-group 16-
 
 
 ANA  positivity  based on  obstetric code
Gravida 
G3 (n=42) 
G4 (n=14) 
G5 (n=2) 
G6 (n=2) 
     
          This table shows seropositivity of women with BOH based on their 
obstetric code. Of the total 42 women with 3
were ANA positive.14 women with 4
positive. Among 5th and 6
2(11.11%) and 1(5.55%) were positive respectively.
ANA  positivity  based on  obstetric code
 
G4
38.88%
11.11%
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Table - 4 
 
No of samples tested No of ANA positives
42 8 (44.44%)
14 7 (38.88%)
2 2 (11.11%)
2 1 (5.55%)
rd
 gravida, 8 (44.4%),women 
th
 gravida, 7(38.88%) were ANA 
th
 gravida women, with each comprising two, 
(fig 4). 
Fig - 4 
 
G 3
44.44%
G 5
G 65.55%
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Table - 5 
Seropositivity of ANA  based on  number of abortions 
No of 
abortions 
ANA 
positive 
Percentage 
ANA 
positive 
ANA 
negative 
Percetage 
ANA 
negative 
≥2 (n=46) 11 23.9 35 76.1 
<2 (n=14) 7 50 7 50 
 P value > 0.05 (Not significant) 
       
   The above table shows correlation of  ANA positivity with 
number of  abortions. Among women with less than 2 abortions, 
11(23.9%) were ANA positive and 35(76.1%) were ANA negative. 
Among women with more than 2 abortions, 7 (50%) were ANA positive 
and 7 (50%)  were ANA negative . The association between  ANA 
positivity and number of abortions is not  statistically 
significant.(P>0.05).(fig 5). 
  
 Seropositivity based on number of abortions
Distribution of cases based on trimester of pregnancy 
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7
≤2 abortions
<2 abortions
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Fig - 5 
 
Fig – 6 
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22%
 
 
 Correlation of  ANA
Trimester of 
pregnancy 
ANA 
positive
1st trimester 
(n=15) 
2nd trimester 
(n=37) 
 
P value >0.05 (not significant)
      The above table 
trimester of pregnancy. Of the 15 women in 1
ANA positive and 9 (60%) were negative. Of the 37 women in 2
trimester, 11 (29.7%) and 26 (70.3%) were ANA positive and negative 
respectively. The association between  ANA positivity and  trimester of  
pregnancy shows no statistical significance.(P>0.05).
Correlation of ANA positivity based on trimester of pregnancy
0
5
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30
1st 
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Table -6 
 based on trimester of pregnancy
 
Percentage 
ANA 
positive 
ANA 
negative 
Percentage 
6 40 9 
11 29.7 26 
 
 shows evaluation of ANA positives based on 
st
 trimester, 6 (40%)were  
(fig 6,7).
Fig – 7 
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ANA 
negative 
60 
70.3 
nd
 
 
 
 
-)
 Co-morbid conditions in women with BOH
Association of  BOH cases with  co
Co-morbid 
disesases 
(hypothyroisism, 
HT, GDM) 
positive
Present (n=16) 10
Absent (n=44) 8 
P value <0.001 (Statistically significant)
           The above table shows association of other systemic disease which 
includes hypothyroidism, hypertension, diabetes mellitus with the ANA 
results in present pregnancy. Among 16 cases, with other systemic 
31%
70 
Fig – 8 
 
 
Table 7. 
-morbid conditions
ANA 
 
Percentage 
positivity 
ANA 
negative 
 62.5 6 
37.5 36 
 
44%
25%
Hypothyroidism Hypertension Diabetes
 
 
Percentage 
positivity 
18.18 
81.82 
 disease, 10 were ANA positive  and 6 were ANA negative.Eight patients  
who showed ANA positivity, did not have any associated disease. The 
association between persons with co
results were considered to be extremely statistically  
significant.(P<0.0001)
Association of BOH cases with co
   
 
 
0%
co-morbid dis (+)
co=morbid dis(-) 8
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-morbid conditions and their ANA 
 (fig 8,9) 
 
Fig – 9 
-morbid conditions
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ANA(-)
Column1
 Evaluation of ANA 
 
Cases (n=60) 
Controls (n=60) 
Total 
 P value < 0.001( Statistically significant)
      Among 60 cases with BOH, 18(30%) tested positive for ANA by 
immunofluorescence and 42(70%) were ANA negative. Of the total 60 
multigravid women, 5(8.3%) of them tested positive for ANA by IFAT 
and the remaining  55(91.66%) were negative. The association between  
women with BOH and multigravid controls,using immunofluorescence  
was considered to be statistically significant.
Evaluation of ANA  among cases and controls using 
0
Cases
Controls
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Table - 8 
among cases and controls using 
Immunofluorescence 
              IFAT (+)                 IFAT(
Cases Percentage Cases Percentage
18 30 42 70 
5 8.3 55 91.66
23 38.3 97  
 
(fig 10)  
Fig – 10 
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 Distribution of HEp
HEp-2 cell pattern 
Homogenous  
Anti-centromere 
Fine speckled 
Coarse speckled 
Others- Vimentin, 
Nuclear rim  
          
 This table shows distribution of HEp
IFAT positives which includes both cases and controls.Of
positives, homogenous pattern were seen in 8(44.44%), anticentromere 
pattern in 6(26.08%), fine speckled in 4(17.39%), coarse speckled pattern 
in3(13.04%), vimentin and nuclear rim pattern were  seen in 2(8.69%) 
patients respectively.(fig11) 
Distribution of HEp
fine-speckled
17.39%
Coarse-speckled
13%
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Table - 9 
-2 cell pattern among IFAT positives
No of positives Percentage positivity
8 44.44
6 26.08
4 17.39
3 13.04
2 8.69
-2 cell pattern among the 23 
  
Fig - 11 
-2 cell pattern in BOH cases
homogenous
44.44%
anti-centromere
26.08%
 
 
 
 
 
 
 
 the 18 
 
 
Others-
vimentin, nuclear 
rim
9%
 Grading of fluorescence intensity among IFAT positives
Grading 
3(+) 
2(+) 
1(+) 
Borderline 
 
        This table  shows
positive patients. 3(+) positive were seen in 5(21.7%) patients, 2(+) 
positive were seen in 6(26%) patients,1(+) positive in 11 (47.8%) patients 
and borderline  positive in 1(4.34%)  patient.
Grading of fluorescence intensity among IFAT positives
0
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Table - 10 
No of positives Percentage positivity
5 21.7
6 26
11 47.8
1 4.34
 grading of fluorescence intensity among  the 23 
(fig 12) 
Fig – 12 
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 Evaluation  of  seropositivity among  BOH cases and 
 
              
Cases
Cases (n=60) 19
Controls (n=60) 4 
Total 23
  P value <0.001 (Statistically Significant)
 Among 60 cases with BOH, 19(31.6%) tested positive for ANA by 
ELISA and 41(68.33%) were ANA negative. Of the total 60 multigravid
women, 4(6%) of them tested positive for ANA by ELISA and the 
remaining  56(93.33%) were negative. The association between ANA 
positivity,for women with BOH and controls  were considered to be 
statistically significant.
Evaluation  of  
0 10
Cases
Controls
4.3
4
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Table - 11 
controls using ELISA 
ELISA (+)               ELISA(
 Percentage Cases Percentage
 31.6 41 68.33
6 56 93.33
  97  
 
(fig 13).  
Fig – 13 
seropositivity among  BOH cases and 
controls using ELISA 
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Table - 12 
Comparison  of ELISA and IFAT for ANA positivity  
among cases and controls 
 
 
ELISA IFAT 
No of 
positives Percentage 
No of 
positives Percentage 
Cases(n=60) 19 82.6 18 78.26 
Controls 
(n=60) 
4 17.39 5 21.73 
P value <0.05 Not significant 
 
        This table compares ANA positivity among cases and controls by 
both  ELISA and IFAT method. Among BOH cases 19(82.6%), 
18(78.26%) were positive by ELISA and IFAT method repectively. 
Among  controls  4(17.39%) and 5(21.73%) individuals were positive by 
ELISA and IFAT methods respectively.(fig 14)  
          ELISA reported one more women with BOH as ANA positive, 
which IFAT failed to detect.Among controls, ELISA missed one sample 
as ANA positive while IFAT reported as positive. 
 
 
 
 Comparison of ELISA and IFAT among cases and controls 
Evaluation of ELISA for detecting ANA positivity among  
ELISA 
Positive 
Negative 
Total 
     
 In the above table Enzyme Immunoassay was evaluated against 
IFAT.18 cases were positive by ELISA and IFAT.2cases were ELISA 
positive but negative by IFAT.1 case which was positive by IFAT was 
negative by ELISA.39 cases were negative
0
Cases
Controls
77 
Fig – 14 
Table - 13 
cases with BOH 
IFAT 
 
Positive Negative 
18 2 
1 39 
19 41 
 by both methods.
5 10 15 20
4.3
4
18
5
 
 
 
Total 
20 
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Fig - 15 
Seropositivity and seronegativity of ANA among cases and 
controls by ELISA and IFAT 
              
ELISA  test was evaluated for its sensitivity and specificity against IFAT, 
gold-standard test. 
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 The above table shows sensitivity,
value and negative predictive value of E
97.5% respectively. 
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Fig - 16 
cases with BOH 
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6. DISCUSSION 
             Recurrent pregnancy loss has mutifactorial etiology.Immune 
factors are believed to play a role in it.Causative relationship between 
autoantibodies to phospholipids  in gestational loss have been extensively 
studied, but the role of antinuclear antibodies inrecurrent fetal loss is not 
known. 
         Indirect immunofluorescence method performed on substrate slides 
of cultured human epitheloid cell is indispensable in clinical laborataries 
for the detection of antinuclear antibodies.  Enzyme immunoassay 
(ELISA) kits  for antinuclear antibodies detection have been developed 
and commercialised, but their  usefullness  have not been  studied widely.    
         This study was conducted on 120 pregnant women in two groups.60 
pregnant women with bad obstetric history were evaluated against 60 
multiparous pregnant women The study population mainly consisted of 
women attending antenatal clinic and inpatients in Obstetrics and 
Gynaecology Department, Tirunelveli Medical College Hospital, from 
August 2011 to September 2012. 
6.1 Age-wise distribution 
          In this study, the mean age among cases and controls is around 28 
years. Patton P E52 tested sera from 136 women (84 pregnant and 52 
nonpregnant) for antibodies directed against nuclear antigens, The mean 
ages of the two groups were 32 and 26 years, respectively. A study from 
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Sweden reported the risk of abortion to increase thrice  from 8.7% at age 
24 to 24.7% at age 35. 
6.2 Seropositivity among BOH cases and controls 
          In this study antinuclear antibodies were found in 18(30%) women 
with RPL and 5(8.3%) in the control group.   In retrospective studies, 
antinuclear antibodies were found to be five times more common in 
women with unexplained recurrent miscarriage compared to women with 
successful pregnancies. 
 In the study conducted by Garcia et al53 antinuclear antibodies 
were more prevalent in patients with RPL (30%) ,compared to controls 
(6.6%).Nakatsuka M et al55 in his study reported ANA in 43.5% in 
women with habitual abortion. and 22.4% in the control group.  
 A study conducted by Bustos62 on 118  women with BOH against 
125 controls found no difference between controls and patients with 
antinuclear antibodies.A study conducted by   Ruiz JE63 in Colombian 
women found no  difference in antibodies directed against nuclear 
proteins in women with recurrent fetal wastage when  compared to 
controls. 
6.3  Seropositivity of ANA among  normal pregnant women 
 The occurrence of ANA in normal pregnancy  has been variably 
reported to range from 1-53% .In this study 5(8.3%) women  were found 
to be positive for ANA. Farnam et al50 found an ANA frequency of 
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10.7% among 214 pregnant women at low titres. Similar findings were 
reported by Rosenberg, Baig & Shere et al, Vazqueg-del Mercado et al. 
 Thus ANA may be positive in low titres in normal pregnancy, not 
necessarily being an indicator of collagenosis, some infectious disease 
may be the cause. 
6.4 Seropositivity among women with BOH 
 In this study, of the 60 women with  recurrent fetal losses, 18(30%) 
were found to be positive for antinuclear antibodies. This is comparable 
to studies conducted by Garcia et al53, Xu L54 and Nakatsuka et al55. 
 In the study conducted by Malinowski et al57 the seropositivity of 
ANA was around 51.5% in women with unexplained RPL, and  in the 
study by Ticconi et al it was around 50%. 
 Antibodies directed against nuclear proteins interfer with the 
formation and maturation of placenta and may lead to fetal loss.All forms 
of  cells of fetal origin cross placenta, during normal gestation and reach 
the maternal circulation and tissues, where they remain for long time even 
after delivery, this fetal microchimerism,11 may lead to the development 
of autoantibodies in pregnant women.   
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6.5 Analysis of risk factors 
           This study is composed of 42 women with 3rd gravida comprising 
44.44% positivity in antinuclear antibodies, but the reason to this seems 
to be unclear. 
 Recent articles suggest that the risk of subsequent gestational loss 
is approximately 24% after two abortions, 30% after three subsequent 
abortions.In this study, frequency of women  presenting with ≤2 abortions 
was around 30% and >2 abortions was around 50% .  
 In a study done by Stricker59 on 47 women, the mean number of 
abortions was 3.7. 
 A study in Italy81 with eighty nine women women  with two 
gestational loss and hundred  and five women with three or more 
gestational loss contributes to 45.87% and 54.12% positivity in the study 
and concluded that presence of ANA does not distinguishes women with 
one or more gestational  losses. 
 In the study group51,1 st trimester abortion occurred in  15 women 
of which 40% were ANA positive and in 31 women with 2nd trimester 
abortion , 30% were ANA positive.  
 Autoimmune diseases are the cause of late 1st trimester or early 
mid trimester abortions. In  pregnancy autoantibodies may react against 
trophoblast resulting in sub-placental clots which may interfere with 
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implantation and thereby causing defective placentation. Thrombosis may 
occur, which results clinically in abortions and fetal wastage82,83.  
 In a study conducted by Farnam J 50 to  find out total positive cases 
among  214 antenatal women and in 50 age-adjusted controls , 23 
antenatal women  were found to have antibodies directed against 
antigens,  five (9.2%) were in the II trimester, and 18 (13.4%) were in the 
III trimester.  
  Rosenberg51 evaluated  early, mid, late gestational samples from 
100 women At serum dilutions of 1 in 80, the numbers of samples 
positive in the early, mid, late gestations and cord sera were 18, 21, 21, 
and 15, respectively. At serum dilutions of 1 in 160, the numbers of sera 
positive for antinuclear antibodies in each trimester and in cord sera were 
9, 12. 
 Bahar et al56 conducted a controlled study on 103 patients with 
unexplained recurrent abortions. No difference was found between first 
and second trimester aborters. 
 In this study  co-morbid conditions like hypothyroidism, HT and  
gestational diabetes mellitus were present in 16 women of which 
10(62.5%), were found to have antinuclear antibodies.The most common 
association was with hypothyroidism. These women, would be positive 
for one or more autoantibodies to thyroglobulin or thyroid peroxidase. All 
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these conditions predispose to vasculitis and leads to sub-placental 
thrombosis. 
 A  study conducted by Ticconi et al81 in Italy, suggest that (53.6%) 
of females with recurrent fetal wastage,had   multiple autoantibodies  
along with ANA. 
6.6 Analysis  of immunofluorescence  and ELISA for detection of 
ANA   
 In this study 23 women were positive for antinuclear antibodies 
including 18(30%) of women with BOH and 5(8.3%) controls by  IFAT 
using human epithelioma cell type2 as substrate. Similar findings are 
reported by Garcia et al, Xu L. 
 In a study done by Ogaswarsa84 in America, 301 women with 
unexplained miscarriage, antibodies  directed against nuclear antigens 
was present in 25.2% of study population. 
 Among the nuclear patterns, the most frequent consist of 
homogeneous/peripheral fluorescence (DNA, deoxyribonucleoprotein, 
histones) and speckled fluorescence (RNP,Sm, Ro/SSA, La/SSB); the 
relatively frequent patterns include the centromeric (CENP-A, CENP-B, 
CENP-C), Cytoplasmic patterns are relatively less frequent22. 
 This study revealed homogenous pattern  in 8(44.44%), followed 
by speckled and anti-centromere pattern in 7(38.8%),6 (26.08%) 
respectively. Cytoplasmic pattern was seen in 1(4.65%) individual . This  
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is similar to findings of  Satoh et al35  in  USA, Edwards et al36  in Britain 
and Afemann68 in South Africa. 
           In India Chopra et al67 detected ANA by Immuno-enzyme  method 
using filter paper blood clots in 21 patients with proven autoimmune 
disease and reported homogenous pattern in 11 individuals followed by 
speckled pattern in 10 individuals. 
           A study conducted by Marin49 in normal population and Maddison 
in Spain revealed speckled pattern in almost 50.3% individuals and the 
other patterns were less frequent             
           In this study, 3(+) intensity was noted among 5(21.7%) ,2(+) 
among 6(26%), 1(+) among 11(47.8%) and borderline seen  in 1(4.34%) 
persons.  
         This way of expressing result has the advantage of saving time and 
resources because titration of serum samples is not requested; however, 
the intensity of fluorescence in the working dilution is not always a 
proportional to the antibody concentration, particularly  for centromeric 
and nucleolar patterns in which the reduced amount of antigen makes the 
definition of fluorescence intensity highly subjective and, thus, poorly 
accurate.Equivocal reports must be confirmed by other methods23. 
 In   this study among 120 patients, 19(31.8%) of women with BOH 
and 4(6%) of controls were positive by ELISA.  Bahar et al56  from Saudi 
Arabia, reported 13.6% positivity among cases and 1.2% among controls. 
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 In  this study antinuclear antibodies were positive in 18 (30%) 
cases by IFAT and 19 (31.6%) cases by ELISA. Among controls 
5(8.3%), 4(6%) samples were positive by IFAT and ELISA respectively. 
The ability of test to detect true positives, false positives were 94.7%, 
95.12%.Percentage positivity and negativity of Enzyme immunoassay 
was 90 and 97.5 respectively. 
  A study conducted in Japan by  Kumagai69 screened 257 healthy 
subjects between Enzyme Linked Immunosorbent Assays and IFAT. The 
sensitivity and specificity of Enzyme Linked Immunosorbent Assays 
were 84% and 94%, respectively.  
 Divate et al (2002),70 investigated the sera from 96 patients, and 
found the, ability of test to detect true positives, false positives were 
90.7%, 85.7%.Percentage positivity and negativity of Enzyme 
immunoassay was 89.1%, 87.8% respectively. 
 In Spain, Gonzalez71 found no differences between areas under 
recciever operating characteristic curves for enzyme immunoassay and 
IFAT. 
 Dipti75 in Bangladesh ,tested 40 children with Lupus and found  
IFAT method to be superior than Enzyme Linked Immunosorbent Assay 
for detection of antibodies to nuclear antigens.In this test true positive 
rate by IFAT was 100%, in contrary to Enzyme Linked Immunosorbent 
Assay which was only 55% positive. 
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          A study conducted in Israel73, from 85 sera of patients with 
connective tissue disorders, Enzyme Linked Immunosorbent Assay  to be 
superior than IFAT  for diagnosis of antinuclear antibodies. 
         Despite recent advances in the standardization of the IFAT method 
(automation of the analytic procedure and recognition of the 
immunohistochemical pattern by way of computerized systems), this 
technique  has some methodologic and interpretive limitations. A 
negative finding for ANA on IIF may occur in connective tissue diseases 
owing to the effective absence of antinuclear autoantibodies, paticularly 
the presences of antibodies to very soluble antigens (such as Ro/SSA), or 
the presence of autoantibodies directed against scarce cytoplasmic 
antigens (such as Jo-1 and Ro/SSA). 
           IFAT gives low titre values in few healthy persons. Every one in 
four person will test positive for autoantibodies in lower dilutions85,86. 
Need for skilled microscopist to interpret patterns, high inter-personal 
varaiation may  at times give lower sensitivity when compared to Enzyme 
assays. 
          ELISA appears to suite as a preliminary investigatory tool to 
diagnose autoimmune diseases.This methodology is simple with least 
subjective variation and could be used to screen to large population at a 
time. 
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           Equivocal results in Enzyme Linked Immunosorbent Assay are to 
be  interpreted by other specific methods for autoantibodies.Moreover 
this technique has to be standardised by using samples from community 
and diseased. 
 So immunofluorescence method is superior to EIA, because 
fluorescent patterns  which have clinical implications would be visualised 
only by this methodology4,70. 
 The ideal method should fulfill criteria of clinical sensitivity and 
high specificity, precision and accuracy, ease of execution, limited use of 
technology, quick availability, and contained costs. At present, no method 
exists that fulfills all these requirements22. 
 Western blot4,22 is a qualitative method that furnishes a complete 
pattern of the antinuclear specific antibodies and indicates the 
composition and molecular weight of the different antigenic systems, but 
the proteins used as antigens are modified in their conformation by 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis.  
 This method is used mostly to confirm autoantibody specificity and 
to attempt recognizing antigens different from those listed in the 
preceding guideline. 
 Thus women without an autoimmune disorder history, but with 
complications during pregnancy, have a raised number of autoantibodies. 
This may be due to exacerbation of an undiagnosed autoimmune disorder 
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or an unknown maternal immune reaction. It is not known whether the 
occurrence of autoantibodies, is transient and limited to pregnancy and  
immediate postpartum period, or it is predictive of future immunological 
disease. 
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7. SUMMARY 
 This study was conducted for a  period of 1 year from August 2011 
to September 2012. The study population mainly consisted of women 
attending antenatal clinic and inpatients in Obstetrics and Gynaecology 
Department. Tirunelveli Medical College Hospital, Tirunelveli. 
 A total of One hundred and twenty blood samples collected from  
patients in two groups. One group consisted of 60 women with Bad 
Obstetric History.The other group consisted of 60 multiparous 
women from the age 18-40 years. 
 The mean age among cases and controls is 28 years. 
 Out of 120 patients tested,18 (30%) women with  bad obstetric 
history and 5(8.3%) women among control group were found to be 
positive for antinuclear antibodies 
 The mean age for women with Bad Obstetric History was 28 years. 
Of the 21 (35%)  women tested in 26-30years, 8(44.44%) women 
were  positive. 
 Of the 60 women in study group, women with 3rd gravida 
constitutes 42%, of them 8 (44.4%) women were positive for 
antinuclear antibodies. 
 There was no statistical difference between  seropositivity of ANA 
and number of abortions. 
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 There was no statistical difference in antinuclear antibodies based 
on trimester of pregnancy. Late 1st trimester or early 2nd trimester  
pregnancy loss could be due to autoimmunity. 
 Among the 60 women in study group, co-morbid conditions like 
hypothyroidism, hypertension, diabetes mellitus were observed in 
16(26.6%) women, of which 10 (62.5%) were found to have 
antinuclear antibodies.There was   significant statistical difference 
between ANA positivity and co-morbid conditions. 
  Of the total samples tested, 18(30%) women in study group and  
5(8.3%)  women in control group were found to be positive for 
antinuclear antibodies by Indirect Immunofluorescence using HEp-
2 cell substrate. 
 The most frequent HEp-2 cell pattern observed in the study was 
homogenous in 8(34.7%) followed by anti-centromere in 
6(26.08%). The other patterns observed were speckled, vimentin 
and nuclear rim. 
 Among 23 women, found to be positive for antinuclear antibodies, 
1(+) grading is seen in 11(47.8%) samples, 2(+) grading seen in 
6(26%) samples, 3(+) grading seen in 5(21.7%) samples. 
 Of the total samples tested, 19 (31.6%) women in study group and 
4 (6%)  women in control group were found to be positive for 
antinuclear antibodies by ELISA. 
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 The sensitivity and specificity of ELISA was 94.7% and 95.12% 
respectively.The positive predictive value was 90% and negative 
predictive value is 97.5%. 
 There was no significant difference in detection of antinuclear 
antibodies by ELISA and Immunofluorescence among cases and 
controls. 
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8. CONCLUSION 
 
 The present study shows that autoantibodies play a role in recurrent 
pregnancy loss; and patients with bad obstetric history should be 
evaluated for antinuclear antibodies 
 Since abortions due to immune causes occurs in late 1st trimester or 
early mid-trimester, patients should be screened as early as 
possible. 
 Women who presents with hypothyroidism, hypertension, diabetes 
mellitus  in pregnancy tend to have an associated antinuclear 
antibody, so these patients also to be evaluated. 
 Normal pregnant women have autoantibodies, probably  due to 
some cross-infections which interferes with test result. 
 Indirect Immunofluorescence is  superior to identify antinuclear 
antibodies directed against nuclear antigens. 
 ELISA appears to be a screening procedure to rule out negative 
samples.It is easy to perform, accurate, with least interpersonal 
variations and can be used to screen large population. 
 Samples with borderline results are to be confirmed by other 
methods. 
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 Immunofluorescence is  superior, because it can identify different 
patterns, which are specific for certain diseases, which is not 
visualised by Enzyme Linked Immunosorbent Assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.no age spouse age gravida abortion trimester spont/induced vaginal delivery LSCS sys illness treat his contaception
-any VDRL test
TORCH 
panel IFAT res IFAT pattern ELISA res OD Value
1 29 33 4 3 2 spont Nil na nil nil nil non-reactive negative neg neg 0.465
2 34 37 3 2 2 spont Nil na nil nil nil non-reactive negative neg neg 0.488
3 31 36 6 4 1 spont Nil na DM- 3yrs insulin nil non-reactive negative neg neg 0.605
4 27 32 4 3 2 spont Nil na nil nil nil non-reactive positive neg neg 0.396
5 23 28 3 2 2 spont Nil na nil nil nil reactive negative neg neg 0.883
6 29 34 4 3 1 spont Nil na HT nil nil non-reactive negative pos fine speckled pos 3.2
7 25 36 4 3 1 spont Nil na nil nil nil non-reactive negative neg neg 0.489
8 18 22 3 2 2 spont Nil na nil nil nil non-reactive negative pos homogenous pos 2.24
9 33 38 3 2 2 spont Nil na nil nil nil non-reactive negative neg neg 0.544
10 37 38 4 2 1 induced Nil na nil nil nil non-reactive positive neg neg 0.296
11 25 28 3 2 3 spont Nil na nil nil nil non-reactive negative neg neg 0.258
12 27 30 3 2 2 spont Nil na nil nil nil non-reactive negative neg neg 0.239
13 21 28 3 2 3 spont Nil na nil nil nil non-reactive negative neg neg 0.342
14 25 29 4 2 1 spont Nil na hypothroidism-10yrs L-thyroxine nil non-reactive negative pos fine speckled pos 4.41
15 37 40 3 2 2 spont Nil na nil nil nil non-reactive negative neg neg 0.349
16 21 27 3 3 2 spont Nil na nil nil nil non-reactive positive neg neg 0.816
17 22 27 3 2 1 spont Nil na nil nil nil reactive negative neg neg 0.204
18 19 24 3 3 2 spont Nil na nil nil nil non-reactive negative neg neg 0.219
19 26 30 3 2 2 spont Nil na DM- 20 yrs insulin nil non-reactive negative pos coarse speckled pos 2.38
20 33 37 4 2 1 spont Nil na nil nil nil non-reactive negative neg neg 0.495
21 35 39 3 2 2 spont Nil na HT-4yrs insulin nil non-reactive negative neg neg 0.233
22 27 31 4 2 2 spont Nil na nil nil nil non-reactive positive neg neg 0.134
23 19 28 3 2 1 spont Nil na nil nil nil non-reactive negative neg neg 0.258
24 26 30 3 2 1 spont Nil na nil nil nil non-reactive negative neg neg 0.243
ASSOCIATION OF ANTINUCLEAR ANTIBODIES IN PREGNANT WOMEN WITH BAD OBSTETRIC HISTORY
MASTER CHART                   
ASSOCIATION OF ANTINUCLEAR ANTIBODIES IN PREGNANT WOMEN WITH BAD OBSTETRIC HISTORY
S.no age spouse age gravida abortion trimester spont/induced vaginal delivery LSCS sys illness treat his contaception
-any
VDRL test TORCH 
panel
IFAT res IFAT pattern ELISA res OD Value
25 27 31 3 2 2 spont Nil na nil nil nil reactive positive neg neg 0.329
26 36 40 3 2 2 spont Nil na nil nil nil reactive negative neg neg 0.463
27 34 38 3 2 2 induced Nil na hypothroidism-10yrs L-thyroxine nil non-reactive negative neg neg 0.269
28 28 32 3 2 1 induced Nil na nil nil nil non-reactive negative neg neg 0.244
29 36 39 3 2 2 spont Nil na nil nil nil non-reactive negative neg neg 0.574
30 29 33 4 3 1 spont Nil na nil nil nil non-reactive negative pos homogenous pos 1.323
31 25 28 5 3 2 spont Nil na hypothyroidism- 4 yrs L-thyroxine nil non-reactive negative pos homogenous pos 4.42
32 19 27 3 2 2 spont Nil na nil nil nil non-reactive negative neg neg 0.366
33 28 33 3 2 3 spont Nil na nil nil nil non-reactive negative neg neg 0.912
34 32 35 3 2 2 spont Nil na HT-4yrs nil nil non-reactive positive pos nuclear rim- B neg 0.433
35 36 39 3 2 2 spont Nil na DM, HT-6yrs insulin nil non-reactive negative neg neg 0.416
36 30 36 3 2 1 spont Nil na nil nil nil non-reactive negative neg neg 0.774
37 20 27 3 2 2 spont Nil na nil nil nil non-reactive negative neg neg 0.877
38 27 31 3 2 3 induced Nil na DM-25yrs insulin nil non-reactive negative neg neg 0.568
39 19 27 3 2 2 spont Nil na nil nil nil non-reactive negative neg neg 0.231
40 33 38 3 2 2 spont Nil na nil nil nil non-reactive negative pos fine speckled pos 1.22
41 25 26 3 2 3 spont Nil na nil nil nil non-reactive negative neg neg 0.312
42 26 31 3 2 2 spont Nil na nil nil nil non-reactive negative neg neg 0.289
43 20 28 3 2 2 spont Nil na nil nil nil non-reactive positive neg neg 0.42
44 38 42 3 2 1 spont Nil na HT-4yrs nil nil non-reactive negative neg neg 0.561
45 25 26 3 2 2 spont Nil na nil nil nil reactive negative neg neg 0.501
46 21 26 4 3 1 spont Nil na nil nil nil non-reactive negative neg pos 2.9
47 30 33 4 3 3 spont Nil na DM, HT-6yrs nil nil non-reactive negative pos anti-centromere pos 4.8
48 28 34 4 2 2 induced Nil na nil nil nil non-reactive negative pos anti-centromere pos 3.86
49 26 36 3 2 2 induced Nil na MS- since childhood nil nil non-reactive negative neg pos 4.12
MASTER CHART                   
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S.no age spouse age gravida abortion trimester spont/induced vaginal delivery LSCS sys illness treat his contaception
-any
VDRL test TORCH 
panel
IFAT res IFAT pattern ELISA res OD Value
50 29 37 3 2 1 spont Nil na hypothroidism-4 yrs L-thyroxine nil non-reactive negative pos coarse speckled pos 3.5
51 34 35 5 3 2 spont Nil na nil nil nil non-reactive negative pos homogenous pos 5.613
52 31 37 6 4 3 spont Nil na nil nil nil non-reactive negative pos homogenous pos 5.11
53 24 28 3 2 2 spont Nil na hypothyroidism -5yrs L-thyroxine nil non-reactive negative pos anti-centromere pos 3.9
54 27 30 3 2 2 spont Nil na nil nil nil non-reactive negative pos anti-centromere pos 5.32
55 30 36 3 2 2 spont Nil na nil nil nil reactive negative neg neg 0.89
56 34 39 3 2 1 spont Nil na hypothyroidism- 5 yrs L-thyroxine nil non-reactive negative pos homogenous pos 5.213
57 21 27 3 2 2 induced Nil na nil nil nil non-reactive negative neg neg 0.882
58 37 40 3 2 2 spont Nil na nil nil nil non-reactive negative neg neg 0.662
59 29 32 4 2 3 spont Nil na nil nil nil non-reactive negative pos homogenous pos 4.78
60 31 38 4 3 1 spont Nil na hypothyroidism- 3 yrs L-thyroxine nil non-reactive negative pos anti-centromere pos 1.99
C1 26 29 3 nil 3 nil yes na nil nil yes non-reactive not applicable pos homogenous neg 1.23
c2 28 37 3 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.651
c3 32 33 3 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.307
c4 20 26 2 nil 1 nil yes na nil nil nil non-reactive not applicable neg neg 0.901
c5 21 26 3 nil 3 nil not applicable yes nil nil nil non-reactive not applicable neg neg 0.262
c6 27 31 3 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.612
c7 30 34 4 nil 3 nil yes na nil nil nil non-reactive not applicable neg neg 0.424
c8 25 30 3 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.513
c9 26 31 3 nil 1 nil yes na nil nil nil non-reactive not applicable neg neg 0.555
c10 36 39 4 nil 1 nil yes na nil nil nil non-reactive not applicable neg neg 0.346
c11 24 26 3 nil 2 nil yes na nil nil yes non-reactive not applicable neg neg 0.502
c12 31 36 3 nil 2 nil yes na nil nil nil non-reactive not applicable neg pos 2.29
c13 35 39 3 nil 2 nil not applicable yes nil nil nil non-reactive not applicable pos vimentin pattern neg 0.426
c14 28 32 3 nil 1 nil yes na nil nil nil non-reactive not applicable neg neg 0.638
S.no age spouse age gravida abortion trimester spont/induced vaginal delivery LSCS sys illness treat his contaception
-any
VDRL test TORCH 
panel
IFAT res IFAT pattern ELISA res OD Value
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c15 25 37 3 nil 1 nil yes na nil nil nil non-reactive not applicable neg neg 0.393
c16 29 33 3 nil 1 nil not applicable yes nil nil nil non-reactive not applicable neg neg 0.709
c17 20 27 2 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.728
c18 37 41 4 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.392
c19 21 25 3 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.441
c20 19 24 2 nil 2 nil yes na nil nil yes non-reactive not applicable neg pos 2.11
c21 27 31 2 nil 3 nil yes na nil nil nil non-reactive not applicable neg neg 0.342
c22 36 40 2 nil 3 nil yes na nil nil nil non-reactive not applicable neg neg 0.29
c23 30 33 4 nil 2 nil not applicable yes nil nil nil non-reactive not applicable pos coarse speckled pos 1.99
c24 24 28 3 nil 2 nil not applicable yes nil nil nil non-reactive not applicable neg neg 0.311
c25 27 31 4 nil 3 nil yes na nil nil nil non-reactive not applicable neg neg 0.342
c26 26 32 3 nil 1 nil yes na nil nil nil non-reactive not applicable neg neg 0.211
c27 22 26 3 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.39
c28 31 36 3 nil 2 nil yes na nil nil yes non-reactive not applicable neg neg 0.611
c29 21 25 3 nil 2 nil not applicable yes nil nil nil non-reactive not applicable neg neg 0.917
c30 28 32 3 nil 1 nil yes na nil nil nil non-reactive not applicable neg neg 0.342
c31 29 40 3 nil 3 nil yes na nil nil nil non-reactive not applicable neg neg 0.267
c32 34 38 5 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.438
c33 24 27 2 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.511
c34 37 41 3 nil 3 nil not applicable yes nil nil nil non-reactive not applicable neg neg 0.574
c35 30 36 4 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.325
c36 26 31 3 nil 2 nil not applicable yes nil nil yes non-reactive not applicable neg neg 0.388
c37 28 34 2 nil 2 nil yes na nil nil yes non-reactive not applicable neg neg 0.861
c38 30 34 2 nil 1 nil yes na nil nil nil non-reactive not applicable neg neg 0.79
S.no age spouse age gravida abortion trimester spont/induced vaginal delivery LSCS sys illness treat his contaception
-any
VDRL test TORCH 
panel
IFAT res IFAT pattern ELISA res OD Value
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c39 32 36 2 nil 2 nil not applicable yes nil nil nil non-reactive not applicable neg neg 0.813
c40 35 40 3 nil 3 nil yes na nil nil nil non-reactive not applicable pos anti-centromere pos 1.89
c41 26 31 3 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.631
c42 19 26 3 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.622
c43 36 41 3 nil 1 nil yes na nil nil nil non-reactive not applicable neg neg 0.421
c44 32 36 3 nil 3 nil yes na nil nil yes non-reactive not applicable neg neg 0.712
c45 37 41 2 nil 1 nil yes na nil nil nil non-reactive not applicable neg neg 0.842
c46 26 26 3 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.608
c47 20 28 2 nil 2 nil not applicable yes nil nil yes non-reactive not applicable neg neg 0.419
c48 34 38 3 nil 1 nil yes na nil nil nil non-reactive not applicable pos fine speckled neg 0.222
c49 32 33 3 nil 1 nil yes na nil nil nil non-reactive not applicable neg neg 0.602
c50 28 35 3 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.256
c51 24 30 2 nil 2 nil not applicable yes nil nil nil non-reactive not applicable neg neg 0.326
c52 21 26 3 nil 1 nil yes na nil nil nil non-reactive not applicable neg neg 0.356
c53 21 28 2 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.234
c54 34 37 3 nil 3 nil not applicable yes nil nil yes non-reactive not applicable neg neg 0.632
c55 30 34 2 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.289
c56 30 37 3 nil 1 nil yes na nil nil yes non-reactive not applicable neg neg 0.534
c57 24 26 2 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.328
c58 27 31 3 nil 2 nil yes na nil nil nil non-reactive not applicable neg neg 0.811
c59 22 27 3 nil 1 nil not applicable yes nil nil nil non-reactive not applicable neg neg 0.558
c60 35 40 3 nil 3 nil not applicable yes nil nil nil non-reactive not applicable neg neg 0.431
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Annexure 1                                                
 
 
 
 
ANNEXURE I 
DATA SHEET 
For P.G Dissertation Work on 
Association of Antinuclear Antibodies on Pregnant Women with Bad 
Obstetric History 
I.General information 
Name:                                                                Age:                                      
                                                                          Spouse age:    
Address                                                             Occupation: 
OP/IP  No:                                                         IP- Unit/ward: 
Income:                                                             Urban/Rural: 
Educational status:                                            Occupation of partner: 
 
II Antenatal risk assessment 
Menstrual history: 
LMP:                                                                                         Gravida: 
EDD:                                                                                          Para: 
CEDD:                                                                                       Live: 
Abortion/still birth:                                                                    MTP: 
LSCS:                                                                                        LCB: 
Previous obstetric history: 
Status of baby born: 
III Clinical assessment 
Presenting complaints 
    Bleeding per vaginam:                      
                     Lower abdominal pain:               
                     Expulsion  of  fleshy mass per vaginam:               
                     Vaginal discharge: 
Systemic illness             
                    H/O diabetes mellitus:             
                    H/O hypertension:            
                    H/O tuberculosis:             
                    H/O sexually transmitted diseases:             
                    H/O contraceptive usage:             
                    H/O drug intake     Duration: 
Family history of similar illness: 
Habits: Smoking/ Tobacco/Alcohol 
IV  Clinical Diagnosis: 
V Treatment/advised given in unit: 
VI Follow up of patient(if needed): 
VII  Laboratory investigations: 
Complete blood count 
  Total count:                      ESR: 
  Differential count:                               Hb: 
Blood                                 Urine 
  Sugar :                                 Albumin: 
  Urea :                                                                    Sugar:                
  Creatinine:                    Deposits: 
Blood group: 
VDRL: 
HIV  status: 
Thyroid function test: 
TORCH panel 
USG: 
ANA:                        
            IFAT: 
   Grading:                                             
   Pattern: 
          ELISA: 
 
Date: 
Signature:    
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ABBREVIATIONS 
 
 ANA   -  Antinuclear Antibodies 
 BOH    - Bad  Obstetric History 
 RPL     - Recurrent Pregnancy Loss 
 ENA   - Extractable Nuclear Antigen 
 CLIF    - Crithidia Luciliae Immunofluorescence 
 Farr assay -  Radiol-labelled assay 
 MIA    - Multiplex Immunoassay 
 HEp-2 cell - Human Epithelioma type-2 cell 
 ANCA   - Antineutrophilic Cytoplasmic Antigen 
 FPBC   - Filtered Paper Blood Clots 
 IVIg     - Intravenous Immunoglobulin therapy 
 FITC    - Fluorescein isothiocyanate 
 TMB    - 3,3’,5,5’-tetramethyl benzidine 

